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A. Summary 
Cancer still is one of the medical nightmares of manhood, being one of the major causes of 
death across Europe in this decade. Despite intensive research and multimodal therapy 
strategies, comprehension of tumor development, behavior and treatment remains challenging. 
Cold atmospheric plasma (CAP) offers a tool for both investigation of tumor behavior with 
regard to the role of radicals in tumor metabolism and in addition a possible therapeutic 
application in tumor treatment. Glioblastoma (GBM) is the most frequent brain tumor in adults 
and one of the most lethal and heterogeneous human cancers. Although advances in surgical 
resection, the use of radiotherapy and concomitant chemotherapy have led to improvements in 
median survival, few options exist for the management of recurrent or resistant tumor sub – 
populations of GBMs. In this work, the impact of CAP treatment on human glioma cell biology 
including proliferation, induction of apoptosis, cell cycle distribution, clonogenicity and 
migration was examined. CAP application effectively inhibited tumor cell growth, induced a 
strong cell cycle arrest in G2/ M phase and reduced clonogenicity and migration in 
chemosensitive and chemoresistant glioma cells in a dose dependent manner. CAP was able to 
restore the responsiveness of glioma cells with an unfavorable MGMT status towards treatment 
with the chemotherapeutic temozolomide (TMZ) and revealed synergistic effects. Long term 
investigation indicated a consistent effect of the CAP application seven days post - treatment. 
Thus, CAP might be a promising candidate for an intraoperative combination therapy especially 
for patients suffering from GBMs featuring an unfavorable MGMT status and TMZ resistance. In 
addition, selective activity of CAP application towards tumor cells was addressed. Murine 
primary astrocytes treated with CAP showed a delayed cell cycle arrest compared to treated 
tumor cells, indicating a possible ‘therapeutic window’. To overcome the disadvantages of the 
cell culture model, an organotypic brain slice culture (OSC) was established. OSCs enable the 
investigation of tumor treatment by CAP in its microenvironment and simultaneously the 
investigation of CAP effects on healthy, non-tumorous tissue. Immunohistological staining of the 
OSCs 14 days after CAP application indicate the activation of the ATM/ATR signaling pathway in 
tumor cells by CAP treatment. The kinase Cdc25c, a mediator of the G2/ M checkpoint 
mechanism triggered in response to DNA injury, was found to be activated via phosphorylation 
upon CAP treatment. This suggest that CAP modulates cell cycle checkpoint response by either 
inducing genotoxic stress or by creating high intracellular ROS levels leading to DNA damage. 
The data of the present work demonstrate that CAP application could be a therapeutic option 
for glioma treatment in combination with chemotherapy especially in chemoresistant sub – 
populations. Preliminary data on cell selectivity suggest a selective activity of CAP application on 
glial tumor cells. 
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B. Zusammenfassung 
Krebs ist immer noch eine der medizinischen Schrecken der Menschheit, da es sich hierbei um 
eine der häufigsten Todesursachen in Europa in diesem Jahrzehnt handelt. Trotz intensiver 
Forschung und multimodalen Therapieansätzen stellt das Verständnis der Tumorentstehung, 
des Tumorverhaltens und der Tumorbehandlung eine Herausforderung dar. 
Kaltes atmosphärisches Plasma (KAP) ermöglicht sowohl die Untersuchung des 
Tumorverhaltens, hierbei insbesondere die Rolle von Radikalen auf den Tumormetabolismus, als 
auch den Einsatz als therapeutische Anwendung in der Tumorbehandlung. Das Glioblastom 
(GBM) ist der häufigste Hirntumor bei Erwachsenen und zudem einer der tödlichsten und 
heterogensten humanen Krebsarten. Obgleich Fortschritte bei der chirurgischen Entfernung des 
Tumors, dem Einsatz von Bestrahlung und gleichzeitiger Chemotherapie zu einer Verbesserung 
in der mittleren Überlebenszeit geführt haben, existieren nur wenige therapeutische Ansätze 
zur Behandlung von wiederkehrenden oder resistenten Tumor-Teilpopulationen des GBMs.  
In dieser Arbeit wurde die Bedeutung der KAP-Behandlung auf die Zellbiologie von humanen 
Gliomen am Beispiel der Auswirkung auf das Proliferationsverhalten, der Induktion von 
Apoptose, der Zellzyklus Verteilung, der Klonogenizität und des Migrationsverhalten, 
untersucht. Die KAP-Anwendung konnte effektive das Wachstum der Tumorzellen stoppen, 
induzierte einen Zellzyklusarrest in der G2/ M Phase und reduzierte die klonogene Kapazität und 
Migration in chemosensitiven wie auch in chemoresistenten Gliomzellen in einer 
dosisabhängigen Weise. Zudem konnte KAP die Sensitivität von Gliomazellen mit einem 
ungünstigen MGMT Status auf eine Behandlung mit dem Chemotherapeutikum Temozolomide 
(TMZ) wieder herstellen und wies dabei synergistische Effekte auf. Langzeituntersuchungen 
zeigten einen anhaltenden Effekt der KAP-Anwendung auch nach sieben Tagen. Daher könnte 
KAP, speziell bei Patienten die an einem GBM mit ungünstigem MGMT Status und einer TMZ-
Resistenz leiden, ein erfolgsversprechender Therapieansatz sein. Zusätzlich wurde die selektive 
Wirksamkeit der KAP-Anwendung auf Tumorzellen untersucht. Murine primäre Astrozyten 
zeigten eine verzögerte Zellzyklus-Unterbrechung im Vergleich zu behandelten Tumorzellen, 
was auf ein mögliches „therapeutisches Fenster“ hindeutet. Um die Nachteile eines Zellkultur-
Modells zu umgehen, wurden organtypische Kulturen aus Hirnschnitten (OHK) etabliert. OHKs 
ermöglichen die Untersuchung der KAP-Wirkung einerseits auf den Tumor innerhalb seines 
Mikromilieus, als auch zugleich auf gesundes, nicht tumorhaftes Gewebe. Immunhistologische 
Färbungen 14 Tage nach der KAP-Behandlung weisen auf eine Aktivierung des ATM/ ATR 
Signalweges durch die KAP-Behandlung hin. Die Cdc25c Kinase, eine Vermittlerin des G2/ M 
Phase Checkpoints die durch DNA Schädigung ausgelöst wird, wurde per Phosphorylierung nach 
der KAP-Anwendung aktiviert. Dieser Umstand lässt vermuten, dass KAP den Zellzyklus 
Checkpoint entweder über die Produktion von genotoxischem Stress oder durch die Induktion 
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eines hohen intrazellulären ROS Spiegels, welcher dann wiederum zu DNA Schäden führt, 
reguliert.     
Die Resultate der hier präsentierten Arbeit zeigen, dass die KAP-Anwendung in Kombination mit 
Chemotherapie eine therapeutische Option in der Behandlung von Gliomen besonders mit 
chemoresistenten Teilpopulationen wäre. Vorläufige Daten zur Zellselektivität lassen eine 
selektive Wirkung der KAP-Behandlung auf gliale Tumorzellen vermuten. 
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C. Introduction 
1. Cold Atmospheric Plasma (CAP) 
The fourth fundamental state of matter is named plasma as others being solid, liquid and gas. 
Sir William Crookes, an English physicist, first described in 1879 what we know today as plasma. 
In 1929, the term “plasma” was first applied to ionized gas by Dr. Irving Langmuir, an American 
chemist and physicist [1]. Ionization includes that at least one electron is not bound to an atom 
or molecule, respectively converting the atoms or molecules into positively charged ions. The 
plasma state is the most abundant state of all observable matter in our universe. Examples are 
the sun and the stellar wind. On earth this state of matter can be observed as lightening or as 
the aurora borealis. Plasma is defined as an ionized gas that contains equal number of negative 
and positive charged particles, it is quasi-neutral. Neutral particles may well be present. The 
relative number of ions and atoms (the ratio of density of major charged species to that of 
neutral gas, ni = na,) is called the degree of ionization. Both natural and artificially generated 
plasmas are quasi-neutral, which means that concentrations of positively charged particles 
(positive ions) and negatively charged particles (electrons and negative ions) are well balanced. 
The ionization energy, or ionization potential, is typically specified in electron volts (eV) and 
refers to the energy required to remove a single electron from a single atom or molecule. 
Usually very high temperatures and high energy input are needed for ionization. Plasma is 
referred to as being "hot" since at least the electron temperature is high. Sometimes the term 
"cold plasma" is used when the temperatures of the present ions and neutrals are much lower 
than the electron temperature, i. e. the particles in the plasma are not in a thermal equilibrium.  
Numerous plasmas exist far from the thermodynamic equilibrium and are characterized by 
multiple temperatures related to different plasma particles and diverse degrees of freedom. It is 
the electron temperature Te that often significantly exceeds the temperature of heavy particles 
T0 (Te ˃˃ T0). Ionization and chemical processes in such non-equilibrium plasmas are mainly 
determined by the electron distribution function, therefore are not as sensitive to thermal 
processes and temperature of the gas. Plasma in a non-equilibrium state is usually called non-
thermal plasma. An example of non-thermal plasma in nature is the aurora borealis. In many 
non-thermal plasma systems, electron temperature is in order of several eV (1 eV equals to 
11,600 K), whereas the temperature of neutrals and ions is close to room temperature. Non-
thermal plasmas are usually generated either at low pressures or at lower power levels 
compared to thermal plasmas, or in different kinds of pulsed discharge systems. The Surface 
Micro-Discharge (SMD) device used in this study is producing cold, non-thermal plasma at 
atmospheric pressure by short intervals (in the range of 100 ns) of plasma ignition resulting in 
only partial ionization of the ambient air. Thereby, electrons are energized and reach 
temperatures of a few eV while simultaneously the ion temperature remains at room 
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temperature. The overall temperature of the system does not exceed room temperature since 
the ionization degree is at its maximum 10-7. Another possibility of reducing the temperature of 
the plasma system (but not of the electrons) would be to dilute the “hot” plasma components 
by inducing a gas flow. This was realized for the MicroPlaSter – a microwave driven cold 
atmospheric plasma device - where a cold argon gas flow leads to a decrease of the 
temperature of the whole system. The density of the electrons and the ions are quasi neutral 
 (ne = ni; 1010 – 1011 cm-3) at a bright spot of the electrode.  
In a simplified scheme a plasma device is composed of two electrodes, inserted into a chamber, 
which is filled with air or various other gases. By applying electrical power between two 
electrodes and increasing of the applied voltage, the current suddenly increases at a certain 
voltage required for sufficiently intensive electron cascades. If the pressure is low, lower than of 
the order of a few 100 Pa, a glow discharge develops. This presents a low-current, high-voltage 
discharge widely used to generate non-thermal plasma. Such glow discharges are used for 
several semiconductor fabrication processes, such as etching, ashing, deposition.  
Cascades of electrons are produced first due to their low mass and high mobility. Subsequently, 
electrons transmit their energy to all other plasma components, providing energy for ionization, 
excitation, dissociation, and other plasma-chemical processes (figure 1). Emission of light and 
heating are by-products of the plasma generation process. The rates of such processes strongly 
depend on power input and the used gas composition and can often be far from the equilibrium 
distribution. Chemically active plasmas exhibit multi-component systems that are highly reactive 
due to large concentrations of charged particles (electrons, negative and positive ions), excited 
atoms and molecules, reactive species, and UV photons. 
 
 
 
Figure 1: Plasma ignition. Model of plasma production including acceleration of electrons, excitation 
(with light emission) and dissociation of atoms (after collision with accelerated electrons). Heating which 
is a by-product is not displayed.  
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Examples of artificially generated plasmas in application are plasma display panels, fluorescent 
lamps and component analysis using inductively coupled plasmas together with optical emission 
spectroscopy and mass spectrometry. Most plasmas of practical significance, however, have 
electron temperatures of 1 – 10 eV, with electron densities in the range 108–1013 cm–3. This high 
electron temperature gives high reactivity in the system while the whole system can be kept at 
low temperature.   
 
 
2.  Plasma device used in this study 
Currently, several CAP devices with various designations are in use. In general, CAPs relevant for 
biomedical applications can be classified into three groups of plasma due to their 
characteristics: direct, indirect and ‘hybrid’ plasma. 
 
Table 1: Characteristics of different atmospheric low temperature plasmas relevant for biomedical 
applications (modified after Heinlin et al. 2010 [2]) 
 
 Direct plasmas Indirect plasmas ‘Hybrid’ plasmas 
Plasma sources Floating electrode 
dielectric barrier 
discharge (FE-DBD) 
Plasma jet, plasma bullet, 
plasma gun, plasma 
needle, plasma torch (i.e. 
MicroPlaSter) 
Surface micro discharge 
(SMD), barrier coronal 
discharges 
Mode of 
production and 
properties 
The sample to be treated 
functions as the second 
electrode, current flows 
through the sample 
Plasma is produced in 
between two electrodes 
and transported to the 
sample via gas flow 
The mode of production of 
direct plasmas is coupled 
with properties of indirect 
plasmas: ‘Hybrid’ plasmas 
contain a grounded 
electrode - i.e. here the 
sample does not function as 
the second electrode 
Gas Air Noble gas/air Air 
Distance 
between 
device and 
treated sample 
~ mm ~ mm - cm ~ mm 
UV radiation Relatively weak  Relatively high Relatively weak 
Plasma density 
on the sample 
high Low (strongly depends on 
the distance) 
Low (strongly depends on 
the distance) 
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Site of 
production of 
reactive 
species 
RONS are produced in 
the plasma 
RONS are produced by 
mixing plasma and gas/air 
RONS are produced in the 
plasma 
Produced 
plasma species 
Charged particles  
Short life time species 
Long life time species  
Charged particles  
Short life time species 
Long life time species 
Charged particles 
Short life time species 
Long life time species 
Charged particles (i. e. O2+, N2+, Ar+, He+), short life time species (i. e. NO, O, OH) and long life time 
species (i. e. O3, NO2, N2O) are categorized as        dominant,          relatively high and       relatively low 
 
External parameters such as voltage, frequency, surrounding conditions, as well as the distance 
between the CAP electrode and the biological sample, the treatment time and the carrier gas 
influence the CAP chemistry and therefore change the composition and concentration of plasma 
species that reach the sample.  
Using a direct plasma device, the samples (skin, cells, etc.) act as a counter electrode and the 
plasma discharge is produced between the electrode and the sample. A typical example is the 
Floating Electrode Dielectric Barrier Discharge (FE-DBD) developed and tested by Fridman [3], 
[4]. Since the plasma is produced just above the sample, the plasma density as well as the 
density of reactive species is high. Often the ambient air is used for the plasma production and 
the UV emission is rather low. Fridman and colleagues demonstrated bactericidal properties by 
membrane lipid peroxidation in E. coli [5], as well as blood coagulation [6] and induction of 
apoptosis in melanoma cells [7] using a FE-DBD.   
Devices of indirect plasma contain two electrodes for the plasma production. The plasma 
created is transported via gas flow to the sample. Often noble gas, e. g. helium or argon, is 
required as a carrier gas for plasma production. The reactive species are produced by mixing 
with the ambient air. Several devices with this technology are available from small ‘plasma 
needles’ [8], [9] and ‘plasma jets’ [10], [11], [12] to larger ‘plasma torches’ [13], [14].  
As already mentioned in chapter 1 the FlatPlaSter 2.0 used for the experiments in this study is 
based on the Surface Micro Discharge (SMD) technology developed and described by Morfill et 
al. [14]. This device is classified as ‘hybrid plasma’ due to the combined features of indirect and 
direct plasmas. The FlatPlaSter 2.0 is a further development of the FlatPlaSter 1, which is a SMD 
device without housing, thus operating in an open volume. A main characteristic of this 
technique is relatively high density of reactive species produced by the plasma. In addition, the 
electrical current does not flow through the sample.  
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This SMD electrode itself is integrated into a plastic box containing a lid to facilitate a closed 
volume (figure 2B and C). The size of the housing was manufactured to fit a 96-well - plate, 
therefore making in vitro studies simple. The respective samples to be treated can be located 
below the electrode and the distance between the electrode and the sample can be adjusted to 
different heights. The SMD electrode itself is composed of a Teflon plate (insulator of 0.5 mm in 
thickness) which is sandwiched by a planar metal plate (brass sheet electrode of 1 mm 
thickness) and a stainless steel mesh grid (6 mesh inch -1) (figure 2A).  
 
 
A 
 
B  
 
 
C 
 
 
  
Figure 2: A Sketch of the surface micro-discharge electrode (Morfill et al., 2009) and B with housing 
(drawing by T. Shimizu). C SMD FlatPlaSter 2.0 during plasma production with an opened lid. Emission of 
blue light is visible.   
 
By applying high sinusoidal voltage of 8.5 kVpp with a frequency of 10 kHz, micro-discharges are 
generated homogenously across the stainless steel mesh grid, thereby initiating a cascade of 
chemical reactions in the surrounding air. The produced species reach the sample mainly by 
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diffusion, as no airstream or gas jet was applied. The power consumption for the plasma 
discharge is 20 mW/ cm2 and was measured with the Lissajous method using a 0.1 μF 
capacitance [15]. For the treatment times used in this study, the temperature increase was 
measured to 4 degrees above the ambient temperature at maximum. The main ultraviolet (UV) 
components emitted by the device are in the wavelength range between 280 and 400 nm, 
corresponding to the N2 second positive system. Furthermore, negligible intensities of UVC light 
emission are detected. The UV power density was measured to be 25 nW/ cm2. Concerning the 
production of reactive species of the device mean values of approximately 500 ppm for O3, <1 
ppm for NO and 3 ppm for NO2 were measured at the end of the application. 
 
 
3.  Plasma chemistry 
Simulations using computational modeling aim to predict distributions of neutral reactive 
species in plasma at relatively low power density (< 0.1 W/ cm2). The model contains more than 
600 chemical reactions for the analysis of the plasma discharge.  
 
Table 2: Chemical components included in the modulation (Y. Sakiyama et al., 2012 [16]) 
 
 
 
In this modulation a SMD device similar to the FlatPlaSter 2.0 described in chapter 2 was 
modeled as two coupled zero-dimensional models with a discharge layer and an afterglow 
region [16]. The applied voltage frequency equalled 10 kHz, the power density in the discharge 
layer was 0.05 W/ cm−2 and the distance between the discharge layer and the treated surface 
was 10 mm. The system was assumed to be closed processing a gas temperature of 300 K, i. e. 
the plasma gas was confined in a closed volume. The lifetime of the produced charged particles 
(<100 μs) is relatively short since the plasma discharge consists of numerous micro discharges 
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whose duration is typically ~100 ns. The neutral species in the reactive mix are classified into 
short-lived species which are confined to the discharge layer and long-lived species which 
diffuse into the afterglow region. Considering all possible reactions, including electron 
excitation, ionization, dissociation, recombination, attachment and detachment, charge 
transfer, ion recombination and reactions between neutrals, the air plasma and most of its 
chemical components revert back to their original state after a short time period of seconds to 
minutes. 
The modulation showed that most charged particles are quenched within a single cycle (100 μs), 
except NO2+ and NO3- which possess relatively long lifetimes. Neutral species are dominant over 
charged particles. The most abundant species is O3, with roughly 90% being delivered in the 
afterglow by diffusion from the discharge layer, whereas 10% of O3 is locally generated by 
reactions between O, O2 and a third body. Highly reactive neutral species (N, O, OH, NO, O2 and 
HO2) are mainly confined in the discharge layer (around 1 ppm), whereas they are rarely 
available in the afterglow region (less than 0.01 ppm), indicating a quenching of these species in 
the discharge layer [16]. 
Time dependent ozone generation of the SMD device for different power consumptions 
(ranging from 9.5 x 10-4 W/ cm2 to 2.6 W/ cm2) was measured using UV absorption spectroscopy 
at 254 nm in a closed volume. The UV light, emitted by an argon/ mercury lamp, was passing 
through the two diaphragms and collected by an optical fiber. The measurements indicated that 
the ozone density increased monotonically within the first tens of seconds and reached a steady 
state afterwards for input power lower than 0.1 W/ cm2. At higher input power (< 0.1 W/ cm2) 
the average ozone density dropped within 10 seconds after plasma ignition [17](figure 3A and 
B).  
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A 
 
B 
 
 
Figure 3: Time dependent ozone production of the SMD device in air. A Time evolution of the ozone 
density (nO3) produced by the SMD electrode (in a confined volume of 5 cm3) for different power 
consumptions measured with UV absorption spectroscopy at 254 nm [17]. B Time evolution of the ozone 
density with power consumptions of 0.56 W/cm2 and higher. The applied voltage was 15 kVpp. (The 
graphs were taken from Shimizu et al., 2012).  
 
Model calculations suggest that the observed ozone depletion at higher power densities is 
caused by quenching reaction with nitrogen oxides [16]. They are in turn created by vibrational 
excited nitrogen molecules reacting with O atoms. This mode transition from predominately 
ozone (generated at low power consumptions) to nitrogen oxides (produced at high power 
consumptions) displays how SMD plasma can be selected to favor either oxygen or nitrogen 
based chemistry by changing the external parameters.  
Further characteristics of SMD plasmas were estimated in collaboration with the Chemical and 
Biomolecular Engineering Faculty of the University of Berkley. Fourier transformation infrared 
spectroscopy (FTIR) measurements of a SMD electrode with a power consumption of 0.3 W 
/cm2 identified species such as N2O, NO2 and HNO3 (figure 4A). Obviously, the experimental set 
up influences the produced plasma chemistry of the SMD electrode, i. e. a thin film of liquid 
gives a reduced decline rate of O3 (figure 4B).  
 
Introduction 
17 
 
A 
 
B 
 
 
Figure 4: Liquid phase chemistry of the SMD changes with power. A IR absorption spectrum of the 
plasma gas (power consumption 0.3 W/ cm2) in the absence of H2O and B in the presence of a H2O layer 
(manuscript in preparation by Shimizu et al.). 
 
3.1 Characteristics of the Plasma Device FlatPlaSter 2.0 
As described in chapter 2 the used plasma device FlatPlaSter 2.0 is operated at a power 
consumption of 20 mW/ cm2 – i.e. in the low power mode - predominantly producing reactive 
oxygen species (ROS). Detailed measurements confirmed this revealed mean values of 
approximately 500 ppm for O3, <1 ppm for NO and 3 ppm for NO2 at the end of the application. 
The temperature increase for the treatment times applied in this study was measured to 4 
degrees above the ambient temperature at maximum. Main UV components emitted by the 
device are in the wavelength range between 280 and 400 nm and correspond to the N2 second 
positive system (figure 5). Furthermore, negligible intensities of UVC light emission can be 
detected. The UV power density was measured to be 25 nW/ cm2.   
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Figure 5: Optical emission spectroscopy in the low power mode in air. No emission of UVC light, only 
low dose emission of UVB and UVA light could be detected (manuscript in preparation by Shimizu et al.).   
 
Which species reach the sample and therefore induce the specific effects of the SMD device 
depends on the input power, the treatment time and the distance between the electrode and 
the sample.  
 
 
4. Plasma Liquid Chemistry 
As the studies carried out within this thesis mainly include the analysis of eukaryotic cells 
covered by a thin liquid film, it is mandatory to also understand the chemistry/ composition of 
CAP - induced species in liquids following CAP treatment.  
Pavlovich and colleagues therefore measured the key chemical species in CAP treated aqueous 
buffer (PBS) using a SMD device similar to the FlatPlaSter 2.0 [18]. The results revealed that the 
aqueous chemistry corresponds to the air plasma chemistry – i.e. a transition from the ozone 
mode to the nitrogen mode can be observed as the discharge power density increases (figure 6 
A and B). 
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A 
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Figure 6: Liquid phase chemistry of the SMD changes with power density. Measurement of ozone (A) 
and nitrate/nitrate (B) present at different power densities (Pavlovich et al., 2013).  
 
5. State of the Art/ Tumor Treatment with CAP 
A new research field was established in the 1980s when plasma medicine emerged. Since then, 
several developed CAP sources have proven to successfully inactivate bacteria, fungi, viruses 
and spores in a dose-dependent manner [14], [19], [20], [21], [22]. First therapeutic approaches 
in plasma medicine were established in dermatology [23], [24] and wound disinfection [25], [2]. 
Different plasma devices, ranging from plasma jets driven with argon gas to devices using the 
biological sample as a second electrode, were investigated in medical science and also showed 
anti-cancer properties. Clearly, a comparison of the diverse devices is difficult, as the 
experimental setting as well as the used cells vary. A rough overview of the development in 
cancer application of CAP is given as followed.  
In 2009 first results investigating the effects of different CAPs on cancer cells in vitro were 
published [26], [27]. Advanced publications addressing cancers of breast, brain, colon, lung, skin 
and pancreas followed. The main focus in these studies was set on the analysis of growth 
inhibition [28], [29], the inhibition of migration and invasion [30] , the induction of cell cycle 
arrest [31], [32] and the induction of apoptosis in a dose dependent manner [33], [34], [35], 
[36], [37], [38], [39]. Recent experiments on melanoma verified the induction of apoptosis with 
high CAP treatment times, whereas low treatment times were able to induce senescence [40]. 
Successful treatment with CAP of cancers of melanoma and bladder in vivo were achieved by 
Keidar et al. [35]. In addition, a subcutaneous model of glioma using U87MG cells was CAP 
treated. Here, a reduced tumor size after CAP treatment conducted by induction of apoptosis 
and cell cycle arrest was demonstrated [41], [31]. The latest publications on tumor treatment 
with CAP revealed synergistic effects in a combined therapy with gemcitabine chemotherapy in 
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vivo in the case of pancreas carcinoma [42] as well as both in vitro and in vivo efficacy for tumor 
ablation in a murine neuroblastoma model [43]. 
 
 
6.  Glioma 
Gliomas encompass all brain tumors arising from glial cells. They are classified according to their 
histopathology into astrocytomas (referring to astrocytes), oligodendrogliomas (referring to 
oligodendrocytes), oligoastrocytomas (mixed gliomas, contains several types of glial cells) and 
ependymomas (referring to ependymal cells). Astrocytomas are the most common brain tumors 
in adults, accounting for more than 75% of gliomas [44]. The world health organization (WHO) 
grading of CNS tumors established a malignancy scale based on histologic features, i.e. 
infiltration of surrounding tissue, genetic markers of the tumor and disease progression, 
defining four different categories of astrocytomas: grade I is assigned to the more circumscribed 
pilocytic astrocytoma, whereas diffusely infiltrative astrocytic tumors with cytological atypia are 
defined as grade II (diffuse astrocytoma). Those also showing anaplasia and mitotic activity are 
defined as grade III (anaplastic astrocytoma), and tumors additionally showing microvascular 
proliferation and necrosis as WHO grade IV [45]. Glioblastomas, but also embryonal neoplasms 
and gliosarcomas are examples of grade IV neoplasms. Patients suffering from glioblastoma, 
particularly the elderly succumb to the disease within a short time, approximately within 15 
months. 
 
 
7.  Glioblastoma 
Glioblastoma (GBM) is the most common, aggressive and lethal brain tumor in adults. The 
incidence is 3 to 4 per 100,000 people in the United States and Europe. GBM accounts for 12% 
to 15% of all intracranial tumors and more than 50% of astrocytic tumors [44]. This deadly 
disease occurs more frequently in elderly, with a median age of 64 years at diagnosis [46]. The 
incidence rate of GBM cases is 1.6 fold higher in male than in female. Despite new insights into 
glioblastoma pathophysiology, the prognosis for patients diagnosed with this highly aggressive 
tumor remains unfavorable. Current treatment regimens combine surgical resection and radio- 
and chemotherapy, providing an increase in median overall survival of 14.6 months post-
diagnosis [47]. The five – year survival rates are less than 5% for glioblastomas [44]. Despite 
intensive epidemiological studies risk factors for GBM remain unknown. To date, the only 
environmental risk factor linked to glioblastoma is the exposure to ionizing radiation, typically 
during radiation therapy. Several recent studies could not show a significant correlation 
between higher risk of glioblastoma and cell phone use or chemicals like polyvinyl chloride. 
Various rare genetic disorders as Li-Fraumeni syndrome and neurofibromatosis 1 and 2 are 
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associated with increased incidence of glial tumors. Besides these rare inherited syndromes, no 
familiar genetic susceptibility for malignant gliomas could be found [46]. 
 
 
8. Epidemiology and histology 
Histopathologically, GBMs are heterogeneous, infiltrative and proliferative neoplasms showing 
neovascularization and necrosis within the tumor mass. Approximately 95% of all GBMs develop 
de novo (primary glioblastomas), while 5% emerge from WHO grade II or III astrocytomas 
(secondary glioblastomas) [48]. Regarding histology, primary and secondary GBMs can hardly be 
distinguished. Present studies suggest that both forms develop through different genetic 
alterations. Mutation of isocitrate dehydrogenase 1 and 2 (IDH1/ 2) is rare in primary GBMs (5 - 
10%), while it is found frequently in secondary GBMs (> 80%). Genetic alterations that are 
prevalent in primary glioblastomas are loss of heterozygosity (LOH) 10p, epidermal growth 
factor receptor (EGFR) gene amplification and the phosphatase and tensin homolog (PTEN) 
mutations. TP53 mutations, LOH 19q and LOH 22q are prevalent in secondary GBMs, while LOH 
10p and p16INK4a occur equally in primary and secondary neoplasms [49], [48]. At the present 
time the loss of 10p/19q is to be regarded as a prognostic rather than a predictive factor. 
Furthermore, the determination of the promoter methylation of the DNA repair enzyme O6-
methylguanine-DNA methyltransferase (MGMT) has gained clinical importance and is the only 
established prognostic and predictive marker in GBM.  
 
A 
 
 
B  
 
Figure 7: Histology of glioblastoma. A Hematoxylin-eosin staining of a glioblastoma showing necrosis 
and vascularization [50]. B Nissl stained axial brain-section feature a large necrotic area in the right 
cerebral hemisphere and vital Nissl-positive tumor cells infiltrating the surrounding brain tissue. 
Alterations in the left hemisphere are first evidence for a secondary tumor.  
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9.  Treatment of glioblastoma 
Standard therapy of GBMs includes complete resection or biopsy of the tumor followed, if 
feasible, by combined radio- and chemotherapy according to Stupp [51].  Despite this intensive 
therapy, relapse occurs regularly (figure 8). For the treatment of relapse resection followed by 
radio- or chemotherapy with Temozolomide (TMZ) is proposed. TMZ, a DNA alkylating agent, is 
the most successful anti-glioma drug and has added several months to the life expectancy of 
malignant glioma patients. However, for this reason glioblastoma care remains largely palliative. 
 
 
 
Figure 8: Magnetic resonance imaging (MRI) scans of a patient suffering from glioblastoma. Pre-
operative (left), 10 months post-operative (middle) and recurrent one year after the surgery 
(right)(Neurosurgery department TUM, C. Zimmer, 2010).   
 
TMZ is a pro-drug that undergoes spontaneous hydrolysis and is converted to the active 
metabolite 5-(3-methyl)-1-triazen-1-yl-imidazole-4-carboximide (MTIC) [52], [53]. TMZ is 
efficiently absorbed after oral administration, has a schedule-dependent antitumor activity and 
crosses the blood–brain barrier [54]. Conversion of TMZ to MTIC results in the formation of a 
reactive DNA-methylating agent, which is capable of transferring methyl groups to the N7 and 
O6 position of guanine and the O3 position of adenine. Formation of O6-methylguanine (O6-
MG) is believed to initiate futile cycles of mismatch repair (MMR) and double strand breaks [55], 
[56]. Prolonged G2/ M arrest, cellular senescence or induction of apoptosis are possible results 
of O6-MG lesions [57].  
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10. Therapy resistance 
The enzyme O6-methylguanine-DNA methyltransferase (MGMT) is capable of counteracting the 
cytotoxicity induced by chemotherapy [58], [59], [60] - thus tumors expressing high levels of 
MGMT (MGMT positive) are more resistant to alkylating agents than those in which the enzyme 
has become silenced by promoter methylation (MGMT negative). MGMT promoter methylation 
is associated with a favorable outcome and predicts a benefit from alkylating agent 
chemotherapy in patients with newly diagnosed glioblastoma [61], [62], [63], [64], [65] (figure 
9).  
 
 
Figure 9: Promoter methylation of the MGMT gene suppresses protein expression. Model of MGMT 
promoter methylation resulting in the blockage of transcription factor binding to the promoter.  
 
Hegi et al. demonstrated that in 45% of newly diagnosed glioblastoma patients with tumor 
promoter hypermethylation (and therefore MGMT gene silencing), TMZ was effective when 
administered concurrently or sequentially, with an improvement in median survival (21 versus 
12 months) and 2-year survival (48% versus 10%) compared with patients with unmethylated 
tumor MGMT (figure 10) [62]. Nevertheless, there are patients profiting from TMZ treatment 
despite expression of MGMT as well as patients with an epigenetically silenced MGMT promoter 
showing no response to therapy with TMZ [62], [66]. 
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Figure 10: Patient overall survival according to MGMT promoter methylation status. Kaplan-Meier plot 
estimates the differences in survival and evaluates the prognostic value of MGMT promoter methylation 
status (Hegi et al., 2005).  
 
Consequently, 55% of all newly diagnosed glioblastoma cases do not benefit from the addition 
of TMZ [67]. In addition, most tumors acquire resistance towards chemotherapy during 
treatment, accompanied by a change of the methylation status from methylated to unfavorable 
unmethylated MGMT [68], [69].  
Further, a limitation to the established treatment protocol is the tumor’s location within the 
brain. The resistance to therapy is largely a result of the considerable cellular and phenotypical 
heterogeneity that characterizes this particular tumor. The discovery of a subpopulation of cells 
exhibiting stem cell properties within the tumor bulk has profound implications for therapy. 
These so called brain tumor stem cells (bTSC) are thought to be responsible for the origin, 
maintenance and recurrence of glioblastomas [70], [71]. As a result, novel strategies are 
continually being established to improve patient prognosis, quality of life, and overall outcome. 
 
 
11. Objective 
Plasma medicine is an emerging research field that lately attracted a lot of interest. Cold 
atmospheric plasma (CAP) has proven its effectiveness in various medical applications such as 
sterilization of surgical instruments and wound disinfection. Recently, possible appliance of CAP 
in cancer treatment with modified devices aroused interest.  
Despite intensive multimodal treatments including surgery, radiation and chemotherapy with 
temozolomide, the prognosis for patients suffering from glioblastoma remains poor. Especially 
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patients with an unmethylated MGMT promoter do not benefit from treatment with 
chemotherapy, making new treatment options a need.   
The present investigation aimed to characterize the effects of CAP on human glioma cells. Cell 
growth, the induction of apoptosis, clonogenicity, migration and the cell cycle distribution were 
analyzed after CAP application. Special emphasis was placed on the effects of CAP on chemo - 
resistant glioma cells, as these cell populations are believed to give rise to the recurrent tumor. 
Thus, combined treatment of glioma cells with CAP and the chemotherapeutic TMZ in vitro was 
evaluated. A further aim of the present study was to analyze a possible selectivity of CAP 
towards tumor cells compared to non-tumorous cells. Therefore the cell cycle distribution of 
primary murine astrocytes after CAP application was compared to the cell cycle distribution of 
glioma cells after treatment. An orthotopic brain slice culture model for investigation of CAP 
application on tumor tissue and cell selective properties of CAP was established and preliminary 
data ex vivo on CAP effects in tissue were achieved. 
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D. Materials and Methods 
1. Technical devices 
Device Model Producer 
Cell counter Casy 1®  SchärfeSytem, Reutlingen Germany 
Centrifuges 5471R Eppendorf AG, Hamburg, Germany 
 4K15 Sigma, Deisenhofen, Germany 
CO2 incubator HERAcell® Thermo Fisher Scientific Inc, Waltham, MA, USA 
Electrophoresis cell Mini-Protean® tetra cell Bio-Rad Laboratories, Inc., Munich, Germany 
Flow cytometer FACS CaliburTM Becton Dickinson GmbH, Heidelberg, Germany 
Magnetic stirrer  RCT basic IKA®-Werke GmbH & Co. KG, Staufen, Germany 
Microplate reader Asys Expert plus Biochrom AG, Berlin, Germany 
 Infinite F200 PRO Tecan Group Ltd., Männedorf, Switzerland 
Microscopes Axiovert 25 Carl Zeiss AG, Jena, Germany 
 AxioImager Z.1 Carl Zeiss AG, Jena, Germany 
 AxioObserver.A1 Carl Zeiss AG, Jena, Germany 
 AxioCam ICm1 Carl Zeiss AG, Jena, Germany 
 ApoTome Carl Zeiss AG, Jena, Germany 
 Eclipse TS100 Nikon, Düsseldorf, Germany 
Microtome Microm HM 355 Thermo Fisher Scientific Inc, Waltham, MA, USA 
pH-meter EL-30  Mettler-Toledo GmbH, Giessen, Germany 
Power Supply PowerPAC HC  Bio-Rad Laboratories, Inc., Munich, Germany 
Semi-dry transfer cell Trans-Blot® SD  Bio-Rad Laboratories, Inc., Munich, Germany 
Shaker  Minishaker MS1 IKA®-Werke GmbH & Co. KG, Staufen, Germany 
Spectrophotometer NanoDropTM 2000c Thermo Fisher Scientific Inc, Waltham, MA, USA 
Vibratom VT 1200S Leica GmbH, Wetzlar, Germany 
Water bath  WD 14 Memmert GmbH, Schwabach, Germany 
X-ray film processor Konica SRX-101A Konica Minolta GmbH, Langenhagen, Germany 
   
2. Chemicals, reagents and cytostatics 
Substances Abbreviation Producer 
Acetic acid  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Agarose  Biozym Scientific GmbH, Hessisch Oldendorf, 
Germany 
Amino-n-caprioic-acid  Sigma-Aldrich, Munich, Germany 
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Ammonium chlorid NH4Cl Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Ammoniumperoxosulphate APS  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Bovineserumalbumin BSA Bio-Rad Laboratories, Munich, Germany 
Bromphenol-blue  Sigma-Aldrich, Munich, Germany 
Chemiluminescence detection film  GE Healthcare, Munich, Germany 
Chemiluminescence HRP substrate ECL Millipore, Billerica, MA, USA 
Diamidino-phenylindole  DAPI Roche Diagnostics, Mannheim, Germany 
Dimethylsulfoxide DMSO Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Dithiothreitol DTT Sigma-Aldrich, Munich, Germany 
Ethanol   Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Ethidium bromide  Sigma-Aldrich, Munich, Germany 
Formaldehyde   Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Glycerol  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Hämatoxylin-Eosin HE Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Hydrochloricacid HCl Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Hydrogen peroxide H2O2 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Isopropanol  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Lysis buffer (10x)  New England Biolabs, Ipswich, MA, USA 
Magnesium chloride MgCl2 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Methanol  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Meyer’s hemalaun  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
N-Acetyl-L-cysteine NAC Sigma-Aldrich, Munich, Germany 
Nocodazole  Sigma-Aldrich, Munich, Germany 
Nonident P-40  Sigma-Aldrich, Munich, Germany 
Phenylmethylsulfonylfluoride PMSF  Sigma-Aldrich, Munich, Germany 
Phosphate buffered saline PBS PAA, Pasching, Austria 
Phosphatase Inhibitor Cocktail PhosSTOP Roche Diagnostics, Mannheim, Germany 
Propidiumiodid PI Sigma-Aldrich, Munich, Germany 
Rotiphorese® NF-acrylamide/ bis-
acrylamide solution 
 Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Skimmed milk powder  Merck KG, Darmstadt, Germany 
Sodium chloride NaCl2  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Sodium dodecyl sulfate SDS Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Sodium hydroxide NaOH  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Sodium hydrogen carbonate NaHCO3 Merck KG, Darmstadt, Germany 
Temozolomide   TMZ Sigma-Aldrich, Munich, Germany 
Tetramethylethylendiamine TEMED  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
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Transfer membrane Immobilon-P PVDF Millipore, Billerica, MA, USA 
Tris   Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Triton X-100  Sigma-Aldrich, Munich, Germany 
Trypan blue solution  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Tween-20  Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Xylol   Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
   
3. Software 
Software  Software producer 
Adobe® Photoshop® CS5, Adobe® Acrobat® X Suite Adobe Systems incorporated, San Jose, CA, USA 
Axiovision Rel. 4.8.  Carl Zeiss Microscopy, LLC, Thornwood, NY, USA 
EndNote X5 Thomson ISI Research Soft, NY, USA 
FlowJo analysis software Tree Star, Inc., Ashland, OR, USA 
GraphPad Prism® GraphPad Software, La Jolla, CA, USA 
NIS Elements F 3.2 Nikon Instruments Inc., Melville, NY, USA 
      
4. Cell culture 
4.1  Cell culture consumables and additives 
Substances/Materials Abbreviation Producer 
Accutase  PAA, Pasching, Austria 
B-27® Supplement B27  Life Technologies, Darmstadt, Germany 
Basic Fibroblast Growth Factor, human 
recombinant 
bFGF Life Technologies, Darmstadt, Germany 
Cell culture inserts for live cell analysis  ibidi, Munich, Germany 
Cell culture inserts membrane  Millipore, Billerica, MA, USA 
Collagen Type I  Biochrom AG, Berlin, Germany 
Dulbecco's Modified Eagle Medium 
GlutaMAX-I, high Glucose 
DMEM Life Technologies, Darmstadt, Germany 
DMEM/nutrient mixture F-12 ham 
powder 
DMEM/F-12 Sigma Aldrich, Munich, Germany 
D-(+)-Glucose Solution (45%)   Gluc Sigma Aldrich, Munich, Germany 
Epidermal growth factor EGF Millipore, Billerica, MA, USA 
Fetal bovine serum FCS Biochrom AG, Berlin, Germany 
Geneticin G418  Biochrom AG, Berlin, Germany 
Ham’s F-12 NutrientMixture Ham’s F-12 Life Technologies, Darmstadt, Germany 
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Horse serum   HS Sigma Aldrich, Munich, Germany 
Minimum Essential Medium MEM Life Technologies, Darmstadt, Germany 
Mitomycin C from S. caespitosus       Sigma Aldrich, Munich, Germany 
N-2 Supplement N2 Life Technologies, Darmstadt, Germany 
Neubauer hemocytometer  VWR International GmbH, Darmstadt, 
Germany 
Penicillin/Streptomycin P/S Biochrom AG, Berlin, Germany 
Phosphate buffered saline PBS PAA, Pasching, Austria 
Serological pipettes, cell scraper, 
centrifuge tubes 
 SARSTEDT AG & Co., Nümbrecht, 
Germany 
Temozolomide TMZ Sigma Aldrich, Munich, Germany 
Tissue culture dishes/flasks/test plates  TPP Techno Plastic Products AG, 
Trasadingen, Switzerland 
Dissection instruments  Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
 
4.2 Cell culture media 
Media Components 
Astrocyte medium DMEM/F12 supplemented with 2% (v/v) B27, , 100U/ml penicillin, 
100μg/ml streptomycin, 20ng/ml basic FGF, 50ng/ml EGF 
Cell freezing medium 95% FBS, 5% DMSO 
Dissection medium 7.8g DMEM/F-12 powder, 0.6g NaHCO3, 1.45g glucose diluted in 
495ml qH2O, supplemented with, 100U/ml penicillin, 100μg/ml 
streptomycin, sterile filtered, aerated with 95% O2 and 5% CO2 for 
20min before use 
DMEM + FBS DMEM supplemented with 10% (v/v) FBS, 100U/ml penicillin and 
100μg/ml streptomycin 
MEM + FBS MEM supplemented with 15% (v/v) FBS, 100 U/ml penicillin and 
100μg/ml streptomycin 
Slice medium Dissection medium supplemented with  5% (v/v) HS, 5% (v/v)  FCS, , 
100U/ml penicillin, 100μg/ml streptomycin, 1% (v/v)  N2 and 2% 
(v/v) B-27  
  
5. Buffers and solutions 
Buffer Components 
5x SDS protein sample buffer 312.5mM Tris-Cl pH 6.8, 10% (w/v) SDS, 50% (v/v) glycerol, 
250mM DTT, 0.05% (w/v) bromphenol-blue, ad 10ml H2O 
10x SDS running buffer 250mM Tris, 1.92M glycine, 1% (w/v) SDS, ad 500ml H2O 
10x TBS buffer 24.2g Tris, 80.0g NaCl, pH 7.6 with acetic acid, ad 1000ml H2O 
Blocking buffer 1xTTBS + 5% (w/v) skimmed milk powder 
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Membrane stripping solution 100ml methanol, 100ml acetic acid, ad 1000ml H2O 
Primary antibody solution 1xTTBS 
Secondary antibody solution 1xTTBS + 5% (w/v) skimmed milk powder 
Transfer buffers anode I: 300mM Tris, 20% (v/v) methanol, ad 500ml H2O  
anode II: 25mM Tris, 20% (v/v) methanol, ad 500ml H2O  
cathode: 25mM Tris, 20% (v/v) methanol, 40mM amino-n-
caprioric-acid  
ad 500ml H2O 
Washing buffer (TTBS)  1xTBS, 0.1% (v/v) Tween20 
     
6. Antibodies 
Antibody Dilution Producer 
Anti-mouse HRP-linked pAb 1:10000 New England Biolabs, Frankfurt, Germany 
Anti-rabbit HRP-linked pAb 1:10000 New England Biolabs, Frankfurt, Germany 
ChK1, rabbit pAB 1:200 New England Biolabs, Frankfurt, Germany 
Cleaved Caspase 3, rabbit pAB 1:2000 New England Biolabs, Frankfurt, Germany 
Cleaved Caspase 9, rabbit pAB 1:2000 New England Biolabs, Frankfurt, Germany 
Cleaved PARP1 (Asp214), rabbit pAb  1:1000 New England Biolabs, Frankfurt, Germany 
Caspase 3, full length, rabbit pAB 1:5000 New England Biolabs, Frankfurt, Germany 
Caspase 9, full length,rabbit pAB 1:5000 New England Biolabs, Frankfurt, Germany 
GAPDH (clone GAPDH-71.1), mouse mAb 1:50000 Sigma-Aldrich, Munich, Germany 
GFAP, rabbit pAB 1:100 Dako, Jena, Germany 
MGMT, rabbit pAb 1:2500 New England Biolabs, Frankfurt, Germany 
MIB 1, mouse mAb 1:50 Dianova, Hamburg, Germany 
mt p53, mAB 1:200 Dako, Jena, Germany 
PARP1 rabbit, pAB 1:1000 New England Biolabs, Frankfurt, Germany 
Phospo-Cdc25c (S216), rabbit pAB                  1:200 New England Biolabs, Frankfurt, Germany 
Phospho-Histone H2A.X (Ser139), rabbit 
pAb 
1:1000 New England Biolabs, Frankfurt, Germany 
    
7. Cultivation and cryopreservation of GBM cell lines 
The human glioblastoma cell lines LN18 (mtp53) [72], LN18pEGFP (transfected in-house with 
pEGFP-N2 vector by Anne Rappl), LN229 (mtp53) [72] and U87MG [73] were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% (v/v) FBS and antibiotics under standard 
cell culture conditions at 37°C and 5% CO2. T98G (mtp53) [74] glioblastoma cells were provided 
by Dr. Inge Tinhofer (Charité University Hospital, Berlin, Germany) and were maintained in 
Minimum essential medium (MEM) supplemented with 15% (v/v) FBS and antibiotics. Adherent 
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GBM cells were passaged twice weekly. Therefore, cells were washed with PBS, accutase was 
applied for cell detachment and cells were seeded in fresh media.  
For cryopreservation, cells were harvested at 70% confluence and dissolved in freezing medium. 
After gradual freezing for 2 days at -80°C, cells were stored at -180°C in liquid nitrogen.  
 
 
8. Primary cell culture 
Primary astrocytes were provided by the group of Prof Magdalena Götz, HelmholtzZentrum, 
Munich. Primary cells were isolated from fetal mice brain according to Heins [75] and cultivated 
as a single cell suspension. Single cells were cultured in astrocyte media under standard cell 
culture conditions at 37°C and 5% CO2. 
 
 
9. Cell authentication and Mycoplasma-test 
Authentication of the human cell lines LN18, LN229, U87MG and T98G was performed prior to 
the experiments by analyzing microsatellites with Cell ID™ Systems (Promega Corporation, 
Madison, USA). Therefore genomic DNA was isolated with QIAamp® DNA Mini Kit (Qiagen, 
Hilden, Germany). Following purification, 2 ng DNA was used as template with Cell ID™ 
SystemPCR Master Mix. After DNA amplification, nine human loci, including D21S11, TH01, 
TPOX, vWA, Amelogenin, CSF1PO, D16S539, D7S820, D13S317 and D5S818 were analyzed as 
described by the manufacturer with capillary electrophoresis. STR (short tandem repeat) 
genotype was evaluated with GeneMapper® ID software and compared to data available on the 
ATCC-LGC Standards homepage (LGC Standards, Wesel, Germany).  
Regularly all used cell lines were tested by a nested PCR for mycoplasma infections. Therefore 
100 µl of the cell culture supernatant was boiled for 5 minutes at 95°C. Following brief 
centrifugation, 5 µl of the supernatant served as template for the first PCR. The primers, which 
detect 11 species of mycoplasma (M. fermentans, M. hyorhinis, M. arginini, M. orale, M. 
salivarium, M. hominis, M. pulmonis, M. arthritidis, M. neurolyticum, M. hyopneumoniae, M. 
capricolum) and one species ureaplasma (U. urealyticum) were from PCR mycoplasma detection 
set (TAKARA, Otsu, Japan). The product of the first PCR served as template for the second PCR.  
 
 
10. Protein isolation 
For cell lysis, 10x lysis buffer was diluted in H2O and supplemented with 1 mM PMSF and 1x 
PhosSTOP Phosphatase Inhibitor Cocktail. Adherent cells were harvested with a cell scraper 
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after rinsing with PBS. Following 5 minutes incubation with lysis buffer on ice, cell debris was 
pelleted by centrifugation at 13,000 rpm for 10 minutes. The supernatant was transferred to a 
fresh tube and protein amount was determined by NanoDropTM UV-Vis spectrophotometer with 
an absorption measurement at 595 nm.  
 
 
11. SDS-PAGE and Western blotting 
Equal amounts of protein (20 µg) were separated by size performing a SDS-PAGE (sodium 
dodecyl sulfate polyacrylamide gel electrophoresis). The negatively charged SDS binds proteins 
in a constant weight ratio, resulting in fractionation by size. Disulfide bonds are reduced by 
dithiothreitol (DTT). Heating the samples for 5 minutes at 96°C with SDS sample buffer further 
promotes protein denaturation. The stacking gel (5%) contains tris-glycine at pH 6.8 and the 
running gel (12.5%) resolves at a pH 8.8. PageRuler™ plus prestained protein ladder (Fermentas, 
St. Leon-Rot, Germany) was used as molecular weight marker. Gels for PAGE were purchased 
(Mini-PROTEAN TGX Precast Gels; Bio-Rad Laboratories). Separation was done at 200 V for 45 
min with precast gels and at 120 V for 1.5 h with freshly prepared gels. Afterwards, proteins 
were transferred to a methanol-activated PVDF membrane in a semi-dry blot system at 225 mA 
for 40 – 60 min, depending on the molecular weight of the protein of interest. Blotting paper 
(Sartorius blotting paper; VWR International, Darmstadt, Germany) was soaked with transfer 
buffers. Unspecific binding sites were blocked with 5 % skim milk powder in PBS for 1 h at room 
temperature on a shaking device. Incubation with primary antibodies was carried out over night 
at 4°C in the respective dilution. The membrane was washed thrice in TPBS for 10 min each on 
the shaker at room temperature before applying the corresponding secondary antibodies on a 
shaker for 45 min at room temperature. Immunoreactivity was visualized by addition of HRP 
substrate (Immobilon Western Chemiluminescent HRP substrate; Millipore) and exposure to 
chemiluminescence detection film. For an additional detection of the transferred proteins, 
bound antibodies were removed from the membrane by incubation with stripping buffer under 
shaking for 15 min at room temperature. Afterwards the western blot steps were repeated 
starting with the blocking of unspecific binding sites with 5 % skim milk powder.  
 
 
12. Cell viability 
For the investigation of cell viability after the treatment with cold atmospheric plasma (CAP) 
and/or temozolomide (TMZ), 5x 103 cells were seeded on a 96-well plate and grown over night 
until they reached 80% confluence. Cells were CAP treated with or without medium covering 
them (than fresh medium (DMEM) with 1% FCS was added immediately afterwards). TMZ 
treatment (50 µM, 100 µM and 200 µM), if applied in a combined therapy, was carried out 
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immediately after a single CAP treatment. Medium was changed every 24 h and fresh TMZ was 
added for three days consecutively. Controls were kept without medium for the same duration 
as CAP treatment and/ or were DMSO treated in equal concentrations as TMZ. Cells were 
incubated for 48 h at 37°C and 5% CO2 before cytotoxicity of various treatments was estimated 
with colorimetric Cell Proliferation Kit I (MTT) according to manufacturer’s instructions (Roche, 
Basel, Switzerland). The color change was quantified at 595 nm using a scanning multi-well 
spectrophotometer and correlated to the number of viable cells. 
 
 
13. Clonogenicity assay 
Cells were seeded in 6 cm dishes and treated with CAP without medium and/or with TMZ (50 
µM, 100 µM, and 200 µM) afterwards. As described earlier fresh medium was added 
immediately after the CAP treatment. Controls were treated equally. Cells were seeded into 6-
well plates with a total of 150 viable cells per well 24 h after the CAP treatment and allowed to 
form colonies over a time period of 12 days. Fixation and staining of the colonies was performed 
using the DiffQuik Kit (Medion Diagnostics, Düdingen, Switzerland). Colonies of more than 50 
cells were counted.  
 
 
14. Flow cytometry  
Cell cycle analysis was carried out by flow cytometry. Cell nuclei containing different amounts of 
DNA in the cell cycle phases were stained with propidiumiodid (PI). The G1 phase is featured by 
two complete sets of chromosomes (2N). During S phase, DNA is synthesized and the DNA 
amount is intermediate between G1 and G2. In G2 phase, doubled DNA content defines a 
tetraploid stage (4N). Following RNA and protein synthesis, G2 phase culminates in mitosis (M 
phase). Regarding DNA amount, G2 and M phase are indistinguishable.  Apoptotic cells with 
fragmented DNA appear as subG1 population.  
Cells were seeded in 100 mm2 tissue culture dishes (1× 106 cells/ dish), allowed to attach 
overnight, and CAP and/or TMZ treated for the indicated times and indicated concentrations. 
Controls were treated equally. For FACS analysis cells were washed twice in phosphate buffered 
saline (PBS) and fixed in ice-cold 70% methanol at 4°C for at least 2 h. Afterwards cells were 
washed with PBS and then incubated with 100 µg/ ml of RNase A (Sigma-Aldrich, Hamburg, 
Germany) for 20 min at 37°C and stained with PI (50 µg/ ml). Cell cycle distribution was analyzed 
using the BD FACS Calibur (Becton and Dickinson, Heidelberg, Germany) counting 10,000 events 
per determination. Doublet discrimination and analysis of cell cycle distribution was performed 
with FlowJo analysis software.  
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15. Migration 
Cells were plated on 6-well dishes in cell culture inserts (ibidi) to obtain a defined cell free gap 
suitable for migration assays. Inserts were removed 24 h after cell seeding and CAP treatment 
was applied for indicated times without medium. Fresh medium was added and gap size was 
measured at three randomized positions 4 h, 24 h and 48 h after CAP treatment.  
 
 
16. Organotypic slices cultures (OSCs) 
Organotypic cultures of brains were obtained from newborn C57BL/6 mice (P1 - P3). After 
decapitation, the brains were rapidly removed and placed into ice-cold dissection medium, 
which was aerated with 95% O2 and 5% CO2 prior to use and the olfactory bulb and the 
cerebellum were removed. The remaining desired parts of the brain were embedded in 1% low - 
melting agarose. The brains were cut out in cubes from the agarose and glued onto the support 
of the vibratom using Roti Coll I (Carl Roth GmbH + Co. KG, Karlsruhe, Germany), in proper 
orientation. Brains were cut in 300 µm-thick coronal slices using a vibratom (amplitude setting 
was 0.3mm with a speed of no faster than 0.5 mm/sec) and transferred onto membranes filters 
in a collagen mix (320 µl cell matrix type I-A mixed with 120 µl 5x DMEM mixed with 60 µl 
reconstitution buffer). Collagen was removed from the slices as much as possible and slice 
cultures were incubated at 37°C and 5% CO2 for 15 min to allowed attachment of the slices to 
the membrane. Afterwards slice culture medium was provided and membranes were put above 
omitting the formation of bubbles. Medium was changed after 2 h and every second day 
afterwards (serum free slice medium).    
 
16.1 Cell implantation 
Injection of LN18pEGFP cells into the cortex of the OSCs were performed using a Hamilton 
syringe under the microscope. Cells were trypsinized, centrifuged and resuspended in serum 
free medium to obtain 1x 105 cells/ µl. 0.5 µl of the cell suspension was applied over 1.5 
minutes. 24 h after implantation slices images were taken and CAP was applied afterwards four 
times within the next 48 h without medium. Further images were taken 14 days after CAP 
treatment and slices were fixed in 4% formalin and embedded in paraffin using HistoGel 
(Thermo Fisher, Waltham, MA). 
 
 
17. Immunhistochemistry of paraffin slides 
Paraffin embedded tissue was cut in 3 µm sections and mounted on glass slides for incubation 
at 50°C. For immunohistochemistry the Dako REALTM Detection System Peroxidase/DAB+ Kit (K 
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5001) (Dako, Jena, Germany) was used according to the protocol with slight modifications. 
Briefly, paraffin slices were de-paraffinized by incubation twice in xylol (15 min each). 
Rehydration of the slides in 100%, 95%, 85%, 60%, 30% ethanol (4 min each) was carried out 
and subsequently slides were thoroughly washed in 1x PBS. For heat-mediated antigen retrieval, 
slides were placed in 1x sodium citrate buffer, pH 6.0 and heated to 95°C. Total heating time in 
the citrate buffer in the steamer was seven minutes. Slides were allowed to cool down for 30 
min at room temperature. Three additional washing steps in 1x PBS for a total of 15 min 
followed by an incubation for further 15 min in 3% H2O2 at room temperature.  After further 
washing steps with 1x PBS, samples were blocked with Avidin/ Biotin for 15 min. Pre - 
incubation with 5% normal goat serum for 30 min at room temperature occurred before the 
slices were incubated overnight at 4°C with the desired primary antibody in 1x PBS containing 
5% normal goat serum. The following day, each slide was washed in 1x PBS and incubated in 
secondary antibodies (antibody A and complex B) for 30 min at 37°C. Slides were washed in 1x 
PBS and DAB (3,3'-Diaminobenzidin, concentrations according to the Dako protocol) was 
mounted onto the slides for 5 to 10 min. Afterwards the slides were washed with tap water 
followed by nuclei staining with haemalaun. Slides were covered with glass coverslips and 
images were taken. 
 
 
18. Statistical analysis 
All statistical significances were evaluated using one or two factor analysis of variance (ANOVA) 
followed by Bonferroni post-test. Differences were considered significant at p < 0.001. 
Experiments were repeated thrice if not stated otherwise. 
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E. Results 
1. Effects of CAP on liquids 
1.1 CAP effects on medium 
First, the effects of CAP and its components on liquids were investigated. Among others, pH 
change during CAP application was verified (supplementary data S26). No significant change in 
pH was observed for treatment times up to 320 seconds in DMEM supplemented with 1% FCS. 
Effects on FCS alone or in medium were not found (supplementary data S27). From publications 
and experiments previously carried out by our and other groups it is known that the height of 
the liquid has an effect on the CAP impact on the respective cells. To analyze the effects of CAP 
treated medium on glioma cells, LN18 cells were CAP treated for different time durations in 100 
µl/well of a 96-well plate and medium was either filled up to 200 µl (figure 11A) or medium was 
removed completely after CAP treatment and fresh medium was added (figure 11B). Effects of 
respective CAP treatment on the proliferation of glioma cells were examined using the MTT 
assay. When the medium was filled up, the proliferation was strongly reduced independently of 
the CAP treatment time (figure 11A). In comparison, the medium change led to a dose 
dependent effect of CAP treatment on the proliferation of the cells (figure 11B). 
 
A 
 
B 
 
 
Figure 11: CAP effects on medium. A LN18 glioma cells were CAP treated for the indicated times in 
medium and afterwards the well was filled up with fresh medium to double the amount of medium. MTT 
assay was performed 48 h later. B After CAP was applied on LN18 cells in medium, the medium was 
completely changed to fresh medium and cell viability was measured using a MTT assay. Double 160 sec: 
twice applications of 160 seconds of CAP with a 1 min pause in between. 
Results 
37 
 
 1.2 Storage of pre-treated medium reduces the CAP efficacy 
To further distinguish the effects of CAP on medium, 100 µl/ 96-well DMEM was pre - treated with CAP 
and kept at 37°C and 5% CO2 for 1 h, 12 h and 24 h, before applying solely the pre-treated medium to the 
cells. Effects of the pre - treated medium with incubation time on cell proliferation were compared to 
the treatment of cells with medium which was exposed to CAP immediately before applying to the cells 
(figure 12). The results show that cell viability of glioma cells is reduced if the cells are incubated with pre 
- treated medium. Furthermore, the data confirms that CAP “activated” medium reveals effects on 
cancer cells upon storage, nevertheless reduced effects of CAP on the cell viability were observed for 
storage times of 12 h and 24 h.  
 
 
 
 
Figure 12: Pre-treated medium is effective in reducing cell proliferation. DMEM supplemented with 1% 
FCS was pre-treated with CAP without cells. Pre - treated medium was either immediately applied to 
LN18 cells (“directly”), or stored at 37°C for 1 h, 12 h or 24 h and afterwards applied to the cells. Viability 
was detected using MTT assay. 
 
1.3 Treatment of glioma cells in minimized amounts of medium  
To decline of the CAP effects on liquids and to resemble the situation in the patient, LN18 
glioma cells were treated with only a thin film of liquid covering them (referred to as w/o 
medium).  Keeping the cells with only a thin film of medium for time durations of up to 240 
seconds did not significantly change the viability of the cells (figure 13A). Upon treatment 
between 10 seconds and 240 seconds with CAP w/o medium, a strong reduction of cell viability 
was achieved when normalized to the control which was kept w/o medium for the indicated 
times. Henceforth the treatment with CAP was performed after sucking off the medium from 
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the cells followed by addition of fresh medium immediately after the treatment. Comparison of 
the effects of CAP on the viability of LN229 (figure 13B) and LN18 (data not shown) glioma cells 
indicated that CAP was effective in reducing the proliferation either for treatment with or 
without medium, nonetheless the CAP effect was less pronounced when treated in medium 
(figure 13B).  
 
A 
 
 
 
B 
 
 
 
 
Figure13: A LN18 glioma cells were kept without medium to investigate differences in proliferation by 
only having a thin film of liquid on the cells for up to 240 seconds. Cells were CAP treated without 
medium for the indicated times and cell viability was measured 48 h afterwards. B LN229 cells were 
either CAP treated in 100 µl medium or treated while the medium was sucked off and fresh medium was 
added to the cells subsequently after treatment. Proliferation was detected using the MTT assay.  
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2. Effects of CAP on TMZ -resistant and -sensitive glioma cell lines 
2.1 CAP treatment inhibits cell proliferation in MGMT positive and MGMT negative glioma 
cell lines 
Several tumor biology studies identified the prognostic role of O6-methylguanine-DNA 
methyltransferase (MGMT) status in patients with newly diagnosed glioblastoma. Thus, newly 
diagnosed glioblastoma can be stratified into two prognostic groups based upon MGMT 
promoter methylation status. Promoter methylation of the MGMT gene predicts benefit from 
chemotherapy with the standard chemotherapeutic temozolomide (TMZ), whereas patients 
with an unmethylated promoter status do not benefit from chemotherapy. The expression of 
the MGMT protein of the cell lines U87MG, LN229, LN18 and T98G under standard culture 
conditions was illustrated by antibody detection (figure 14A). GAPDH served as a loading 
control. The cell lines U87MG and LN229 that do not express MGMT (MGMT negative, 
favorable) and the cell lines LN18 and T98G that express MGMT (MGMT positive, unfavorable) 
were treated with TMZ for three days consecutively and cell viability was measured afterwards 
(figure 14B). Treatment with TMZ was able to reduce the viability of the MGMT negative cell 
lines by about 20 - 25%, whereas the viability of the MGMT positive cell lines was only reduced 
to a minor content (T98G) or remained unreduced (LN18). These MGMT positive and MGMT 
negative cell lines were CAP treated with one single application and viability was detected 48 h 
later (figure 14C). A dose dependent inhibition of proliferation by CAP treatment for all cell lines 
was observed. Treatment times of 60 seconds and longer achieved a significant reduction of 
proliferation in the resistant as well as in the sensitive cell lines. 
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Figure14: MGMT promoter methylation predicts response to chemotherapy but does not affect the 
response to CAP. A Immunoblotting of cell lysates for the expression of MGMT protein under normal 
culture conditions. GAPDH served as a loading control. B TMZ was administered in several 
concentrations to glioma cells for three days consecutively and cell viability was detected. C Glioma cells 
were CAP treated once for 30 seconds to 120 seconds and viability was detected 48 h afterwards.     
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2.2 Induction of apoptosis is present to a minor extent after CAP treatment 
The perceived reduction of proliferation in all tested cell lines was conducted by minor 
induction of apoptosis. Immunoblotting of protein lysates gained from LN18 (MGMT positive, 
unfavorable)(figure 15) and LN229 (MGMT negative, favorable) (supplementary data S28) cells 
with antibodies against yH2AX, cleaved PARP1 (figure 15A), Caspase 3 (figure 15B) and Caspase 
9 (figure 15C) as marker for DNA damage was performed. Cleavage of PARP1 was detected 48 h 
and 72 h post - treatment for 120 seconds of CAP treatment and longer, but not after 4 h and  
12 h (data not shown). Phosphorylation of H2AX was demonstrated for a treatment time of 180 
seconds after 72 h, but not after 4 h, 12 h (data not shown) and 48 h. Cleavage of Caspase 9 was 
observed to a minor extent after treatment for 120 seconds and 180 seconds only after 48 h, 
while cleavage of Caspase 3 was detected at none of the mentioned time points. Additionally, 
DNA damage including single strand breaks (ssb), double strand breaks (dsb) and cross linking 
sites at the level of single cells was observable by the comet assay to a minor content 1 h after 
CAP treatment in LN229 cells, but was repaired 24 h afterwards (supplementary data S29). 
Taken these results into account, apoptosis was induced in glioma by CAP treatment only to a 
minor extent, primarily in the first hour(s) after application of CAP.  
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Figure 15: Severe apoptosis is not an early feature of CAP treatment in glioma cells. A Immunoblotting 
of LN18 cell lysates taken 48 h and 72 h after CAP treatment with antibodies for PARP1, cleaved PARP1 
and yH2AX. GAPDH served as a loading control. B Caspase 3 full length was detectable by 
immunoblotting in LN18 cell lysates 48 h after CAP treatment but not the cleaved and therefore 
activated Caspase 3. C Cleavage of Caspase 9 as a marker for induction of apoptosis was not found in 
LN18 cell lysates after CAP treatment.   
 
2.3 Cytolysis is only induced by long CAP treatment durations 
Measurement of released lactate dehydrogenase (LDH) in the medium for the detection of 
cytolysis was performed 2 h, 24 h and 48 h after CAP treatment (figure 16). This assay is based 
on measurement of LDH which is a stable enzyme normally found in the cytosol of all cells but is 
rapidly released into the supernatant upon damage of the plasma membrane. Treatment of 
cells with 1% Triton x-100 served as a positive control. No increased release of LDH after 
treatment for up to 180 seconds was displayed, whereas treatment for 10 minutes resulted in 
about 50 percent increase of released LDH in the medium.  
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Figure 16: Cytolysis is not promoted by CAP treatment in LN18 glioma cells. The release of LDH from 
the cells in the medium 2 h, 24 h and 48 h after CAP exposure up to 600 seconds was assessed. 
Treatment with 1% Triton x-100 served as a positive control. 
 
2.4 Strong induction of cell cycle arrest in MGMT positive and MGMT negative glioma cells 
by CAP treatment 
Based on these findings, we assumed that CAP has an influence on the regulation of the cell 
cycle progression. Thus, cell cycle progression of the MGMT positive and MGMT negative cell 
lines was analyzed 24 h, 48 h and 72 h after CAP exposure (figure 17 and supplementary data 
S30). Treatment times of 120 seconds and longer resulted in a significant arrest in the G2/ M 
phase of the cell cycle in the U87MG (figure 17A), LN229 and T98G (supplementary data S30B 
and S30C) cells. A factor two to four higher amount of cells in the G2/ M phase was found for 
the CAP treated cells compared to the control cells. For the LN18 cell line with an unfavorable 
MGMT status, the arrest was achieved after treatment for 60 seconds (supplementary data 
S30A). The arrest achieved in the tested cell lines U87MG, LN18 and LN229 persisted for at least 
72 h and was independent of the MGMT status. Statistical analysis revealed a significant arrest 
in the U87MG cells (figure 17B) after 120 seconds and longer, whereas the cell cycle progression 
of the LN18 cells (figure 17C) and LN229 cells (supplementary data S30D) was significantly 
inhibited after 60 seconds and longer of CAP treatment.  
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Figure 17: CAP treatment induces G2/ M phase cell cycle arrest in glioma cells. A Representative cell 
cycle distribution of U87MG glioma cells after CAP treatment. Treatment was performed only with a thin 
film of liquid covering the cells. Cell cycle distribution was analyzed using flow cytometry. Similar results 
were observed for the LN229 (MGMT negative) and LN18 (MGMT positive) cells (supplementary results 
S5). B Statistical significances of the observed arrest in the G2/ M phase in U87MG and C in LN18 cells. P-
value *** <0.001 
 
2.5  Induction of cell cycle arrest by CAP application is a long lasting effect in glioma cells 
Long term investigation of the cell cycle progression in LN18 and U87MG cells was conducted 7 
days post - treatment, as an extended duration of the CAP effects on cell cycle regulation would 
represent a benefit regarding the application in a combined therapy with chemotherapeutics. 
Therefore, LN18 and U87MG cells were CAP treated once without medium and cultured for 7 
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days. Cell cycle analysis was performed using flow cytometry. A significant cell cycle arrest in 
G2/ M phase 7 days post - treatment was demonstrated in the resistant cell line LN18 by CAP 
treatment for 120 seconds (figure 18A). Noticeably, the sensitive cell line U87MG featured a 
significant arrest 7 days post - treatment by 120 seconds of CAP application in the S phase of the 
cell cycle (figure 18B). 
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Figure 18: Extended cell cycle arrest was observed post-treatment with CAP. A LN18 and B U87MG cells 
were CAP treated for the indicated times and cell cycle progression was examined 7 days afterwards. P-
value< 0.001. 
 
2.6 CAP reduces the clonogenic potential of glioma cells 
The ability of cells to form clones after treatment with the chemotherapeutic temozolomide 
(TMZ) or CAP was verified (figure 19). Therefore, glioma cells were either TMZ or CAP treated 
and 24 h later 150 cells were seeded and allowed to form colonies over 12 days. Treatment with 
TMZ was able to reduce the clonogenicity in LN18 cells (MGMT positive, unfavorable) only to a 
minor content up to concentrations of 500 µM (figure 19B). The MGMT negative cell line 
(favorable) LN229 was sensitive to treatment with 50 µM TMZ, resulting in a significant 
reduction of clonogenicity. In contrast, a significantly reduced clonogenicity was found after CAP 
treatment for both cell lines independent of their MGMT status (figure 19C). CAP treatment of 
120 seconds strikingly culminated in a complete loss of the clonogenic capacity of the LN18 
cells. 
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Figure 19: Reduced clonogenic capacity of glioma cells treated with TMZ or CAP. Glioma cells were 
either TMZ or CAP treated and 24 h later 150 cells/ well were seeded on a 6-well plate. Colonies formed 
after 12 days were stained and counted. P values *** <0.001. A Picture of the LN18 (MGMT positive, 
unfavorable) cells treated with CAP for 30 seconds, 60 seconds and 120 seconds. Afterwards the formed 
colonies were stained. B Results of the colony formation assay for MGMT positive and negative glioma 
cells (LN18 and LN229) treated with TMZ with concentrations of up to 500 µM. C CAP treatment followed 
by the colony formation assay in either MGMT positive or MGMT negative cells. 
 
2.7 CAP application impairs migration of glioma cells  
To further address the effects of CAP application on glioma cells, the migration ability after CAP 
treatment in LN18 and LN229 cells was investigated. A gap was originated by a cell culture insert 
and cells were CAP treated. Migration of the cells was monitored for 48 h under the microscope.  
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Figure 20: Inhibition of migration in glioma cells after CAP treatment. A LN18 cells and B LN229 cells 
were CAP treated and migration of the cells was monitored over 48 h. Gap size was measured after 4 h, 
24 h and 48 h. C Pictures illustrating the gap directly after the treatment in CAP treated cells or in control 
cells, compared to migration in CAP treated and control cells after 48 h.  
 
Migration was reduced in LN18 cells (figure 20A) after 120 seconds of CAP, but not after 60 
seconds of treatment. A noticeable enlargement of the gap was observed 4 h after CAP 
treatment for both 60 and 120 seconds in the LN229 cell line (figure 20B). Strikingly, the gap 
was even more distinct 24 h and 48 h post - treatment for 120 seconds possibly due to de-
attachment of cells. Migration of LN229 cells with 60 seconds of CAP treatment recovered after 
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48 h. Reduced migration rate and de-attachment of cells was visible in LN18 and LN229 cells 
which were CAP treated for 120 seconds on the pictures taken directly after CAP treatment (0 h) 
and after 48h of incubation after treatment (figure 20C).  
 
 
3. Combined treatment with CAP and chemotherapy 
3.1 Concomitant treatment with CAP and TMZ has a synergistic effect on cell viability in 
MGMT positive and MGMT negative cells 
To investigate the effects of a combined therapy consisting of CAP and the chemotherapeutic 
TMZ in glioma cells, both sensitive as well as both resistant cell lines were CAP treated once 
followed by a consecutively TMZ application for three days. Proliferation of the cells was 
quantified using the MTT assay. Combined treatment with CAP and TMZ leads to a significant 
stronger inhibition of proliferation in the sensitive U87MG (figure 21A) and LN229 
(supplementary data S31) cells, as well as the resistant LN18 (figure 21B) and T98G 
(supplementary data S31) cells compared to separate treatment with CAP or TMZ alone. 
Furthermore, combined treatment with low dose of TMZ (50 µM) and short treatment times of 
CAP (30 seconds in U87MG and LN18, 60 seconds in LN229 and T98G cells) caused significant 
higher suppression of cellular growth as compared to a high dose of TMZ (100 µM) alone.  As 
displayed in figure 21, combined therapy revealed a synergistic effect on cell viability in the 
treated TMZ -sensitive and -resistant glioma cells. Especially low dose TMZ (50 µM) combined 
with short CAP treatment times (30 seconds) clearly showed a synergistic effect rather than an 
additive effect.  
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Figure 21: Concomitant therapy with TMZ and CAP re-sensitizes glioma cells. A U87MG cells were CAP 
treated once and TMZ was applied consecutively afterwards for three days. MTT assay for evaluating the 
cell viability was performed at day four. Controls were kept without medium and/or DMSO treated. B 
The same approach was carried out for LN18 cells, which were CAP treated once and TMZ was applied 
afterwards consecutively for three days. P-value *** <0.001 
 
3.2 Combined therapy induces prolonged G2/ M phase cell cycle arrest  
The LN18 and T98G cell lines, which are known to be fairly resistant to therapy with TMZ, were 
exposed to various TMZ concentrations repeatedly (figure 22 and supplementary data S32). 
Remarkably, only the highest concentration of 500 µM was able to induce a G2/ M phase arrest. 
In contrast, combined treatment of CAP for 60 seconds (single treatment) and TMZ (50 µM, 100 
µM, 200 µM for three days consecutively) indicated a significant cell cycle arrest (figure 22A). 
Especially a combination of 60 seconds CAP and 100 µM TMZ or 200 µM TMZ, respectively, 
turned out to be strongly effective in inhibition of the cell cycle progression (figure 22B).  
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Figure 22: TMZ resistant cells respond with cell cycle arrest to concomitant treatment. A LN18 glioma 
cells were TMZ treated for three days consecutively with 50 µM, 100 µM, 200 µM and 500 µM and cell 
cycle analysis was performed afterwards. In comparison, CAP treatment for 60 seconds was applied once 
to LN18 glioma cells, followed by TMZ treatment with 50 µM, 100 µM and 200 µM for three days 
consecutively. Cell cycle distribution was determined afterwards. B Analysis of the percentage of cells in 
the G2/ M phase after treatment with TMZ and combined treatment with CAP. P-value *** <0.001. 
 
4. CAP displays cell selectivity towards tumor cells 
4.1 Cell cycle distribution in primary astrocytes  
As CAP treatment was effective in glioma cells, the influence of CAP on healthy, non-tumorous 
cells and brain tissue was investigated. Therefore, primary astrocytes were isolated from 
newborn mice and exposed to CAP similar to the tumor cells before (figure 23). Treatment 
occurred with only a thin film of medium covering the cells. The experiment was performed 
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twice. Using flow cytometry the cell cycle progression was determined 48 h after CAP 
treatment. Primary astrocytes did not respond to CAP application with a cell cycle arrest in the 
G2/ M phase, even not when treated for up to 180 seconds. A shift towards the S phase was 
observable for CAP times of 180 seconds, but not for shorter treatment times (figure 23). These 
results indicate that CAP treatment induces different effects in non-tumorous compared to the 
effects induced in tumor cells. Furthermore, the treatment time needed to induce a change on 
cell cycle progression in non-tumorous cells is longer than in tumor cells, suggesting a 
‘therapeutic window’ for the CAP application.      
 
 
 
Figure 23: CAP demonstrates cell selective properties. Primary astrocytes isolated from newborn mice 
were CAP treated and cell cycle progression was analyzed 48 h later. In comparison the cell cycle 
distribution for CAP treated LN18 glioma cells is shown. 
 
4.2 Treatment of LN18pEGFP in organotypic brain slice cultures 
To further explore the impact of CAP on cell selectivity, LN18pEGFP tumor cells were implanted 
in organotopic brain slices cultures (OSCs) from newborn mice and cultured for 14 days. CAP 
was applied twice 24 h and 48 h after implantation. Tumor progression was monitored via 
fluorescence before and 14 days after CAP treatment (figure 24 and supplementary data S34). 
LN18pEGFP revealed similar proliferation behavior towards CAP as LN18 wt cells did in vitro 
(supplementary data S33). Tracking of the LN18 cells via GFP fluorescence revealed that the 
tumor cells were migrated through the OSCs up to a depth of 80 – 160 µm in the slides after 14 
days. CAP treated OSCs seem to express a reduced fluorescence area for treatment times 
between 60 seconds and 180 seconds, even so CAP treatment did not diminish fluorescence in 
vitro (data not shown). There was a remarkable morphological change on the surface of the 
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tissue 14 days after CAP application exclusively in the tumor area, even though CAP was applied 
overall onto the OSCs (figure 24).  
 
 
 
Figure 11: CAP treatment of LN18pEGFP cells in a murine brain slice model. LN18 cells expressing EGFP 
were implanted in freshly prepared brain slices from newborn mice. CAP was applied 24 h after 
implantation of the cells for four times within 48 h and cells were monitored over 14 days.  
 
For immunohistological analyzes of effects on brain tissue and tumor cells slices were fixed 14 
days after four times of CAP application and stained with hematoxylin - eosin (HE), mut p53, 
Glial fibrillary acidic protein (GFAP) and Mib-1 (figure 25A). A precise discrimination between 
normal tissue and tumor cells can be made based upon these staining. p53 is mutated in 
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LN18pEGFP cells, whereas non-tumorous cells express wt p53. GFAP is exclusively expressed in 
astrocytes in the central nervous system, and is not present in LN18 tumor cells (ATCC® CRL-
2610™). The proliferation marker Mib-1 (also known as Ki-67) is solely express in the periphery 
of the tumor, demonstrating a marginal growth of the tumor.  
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Figure 25: Staining of the OSC revealed tumor formation after implantation of LN18pEGFP glioma cells. 
A Immunohistological staining of OSCs with hemotoxylin-eosin (HE), mut p53, GFAP and Mib-1. B The 
activated checkpoint kinase Chk1 can inactivate Cdc25C via phosphorylation at Ser216, thereby blocking 
the transition into mitosis. The control slice presented no phosphorylation of Chk1.  
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4.3 Staining for p-Cdc25c reveals activation of the ATM/ ATR signaling pathway by CAP 
application in OSCs 
OSCs were stained for the phosphorylation of Cdc25c (figure 25B), a key regulator of the cell 
cycle. Cdc25c plays a role in promoting progression from G2 phase to mitosis. The checkpoint 
kinases Chk1 and Chk2 phosphorylate Cdc25c at Ser216 in response to DNA damage or 
unreplicated DNA, thus delaying progression of the cell cycle to provide time to repair the 
damaged DNA or to complete replication. Slices that were CAP treated four times for 120 
seconds demonstrated phosphorylation of the Cdc25c phosphatase in the tumor, whereas 
phosphorylation was not detectable in the tumor of the untreated control slices. Notably, the 
phosphorylation at Ser216 does not occur in mouse cells as mouse Cdc25c does not have an 
equivalent to this residue. 
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F. Discussion 
Over the past decade, cold atmospheric plasmas (CAPs) attracted a lot of interest not only from 
physicists but also from biologists and medical scientist. Cold or non-thermal plasmas offer the 
opportunity of a new, exceeding treatment technology in many fields, such as sterilization of 
medical instruments, disinfection of surfaces, tooth bleaching and application on the skin. 
Newest research gives hope to successful application of CAP in cancer therapy. The present 
work focuses on glioblastoma, as patients suffering from this aggressive tumor still have a poor 
prognosis despite multimodal treatment options including surgical resection, chemotherapy and 
radiotherapy. Temozolomide (TMZ), as the standard chemotherapeutic, in combination with 
surgery and radiation has added several months to the overall survival (from 12.1 to 14.6 
months [51], but is restricted to a subpopulation of tumors with a methylated MGMT promoter 
status [76], [47]. Glioblastomas, which exhibit an unmethylated MGMT promoter and thus 
express the DNA repair enzyme MGMT, are resistant to therapy with alkylating agents like TMZ. 
Treatment options for this resistant subpopulation are of high clinical interest.  
Plasma application on human cells has been investigated since the late nineties. First, the 
effects of so called plasma needles which use helium as a carrier gas were investigated. Often 
cell detachment and cell death were induced [77], [78], [79]. Inspired by these findings, the 
possible application of plasma on cancer cells came into focus. Fridman and colleagues marked 
the beginning of plasma application on tumor cells as they treated human melanoma cells in 
vitro with a FE-DBD device (Floating Electrode Dielectric Barrier Discharge), which produces CAP 
in the surrounding air and furthermore uses the target – in this case melanoma cells - as a 
second electrode [7]. Other publications followed including treatment of cancer cells derived 
from colon, liver and skin. The main focus was set on the analysis of growth inhibition [28], [29], 
cell death [26], [80] and the inhibition of migration and invasion [30] by the usage of various 
plasma devices.  
In the present work we were able to determine the inhibitory effect of CAP produced by a SMD 
electrode on glioma cells in vitro. CAP accomplished a decrease in viability (figure 14), a reduced 
clonogenicity (figure 19) and a robust cell cycle arrest in G2/ M phase (figure 17) in TMZ - 
resistant and TMZ - sensitive cells thus independent of their MGMT status. Moreover, sensitivity 
of resistant glioma cells towards treatment with TMZ was restored by pre - treatment with CAP, 
as indicated by reduced proliferation and a significant cell cycle arrest in G2/ M phase in these 
cells (figure 21 and 22). Besides CAP efficacy in tumor cells and the mechanism(s) of CAP - cell 
interaction, one issue of CAP application in cancer treatment is the selectivity of CAP. First 
results on cell selectivity of CAP in primary astrocytes in vitro disclose an induction of an S phase 
arrest after treatment with CAP for longer treatment times of up to 180 seconds (figure 23). No 
induction of a G2/ M phase arrest was observed even with treatment up to 180 seconds. In 
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contrast glioma cell lines showed a high induction of G2/ M phase arrest already for CAP 
treatment times of 60 seconds to 120 seconds (figure 17 and 23). To further address cell 
selective characteristics of CAP a novel suitable model for glioma was established. Organotypic 
murine brain culture slices implanted with LN18pEGFP cells represent an orthotopic ex vivo 
model for CAP application in a tumor - bearing tissue, providing the possibility to study CAP 
effects on tumor and non–tumorous cells within their histological microenvironment (figure 24 
and 25). 
 
 
1. Effects of CAP on liquids    
The influence of liquids on the CAP effect on cells is under discussion since the first experiments 
with CAP and cells were performed. The device used in the present investigation had no 
influence on the pH of the medium or on the FCS, suggesting that protein modifications may not 
play a major role (supplementary data S26 and S27). In fact, the effect of plasma irradiation is 
depending on depth of the liquid phase (figure 13B) as well as the composition of the medium 
itself for the treatment of bacteria [81], [82]. We made similar observations for the effects on 
cells. Medium change after CAP treatment presented dose dependent effects on cell viability 
(figure 11B), whereas keeping the medium plus adding some fresh medium strongly reduced 
the proliferation for all treatment times (figure 11A). This is probably due to the fact that 
reactive species produced by CAP dissolve into the medium, react further there and the newly 
generated species themselves interact with the cells.  For example, the dissolved ozone initiates 
a reaction with the hydroxyl radical (OH-), resulting in the production of HO2 and the superoxide 
radical (O2−) [83]. Furthermore, O2- is converted to hydroxyl radical (OH-) and nitrogen dioxide 
(NO2) in the presence of the nitrosyl cation (NO+). Once the RONS reach the cell, they might 
activate cell surface receptor and propagate opening of pores and membrane channels. In case 
RONS gain access to different cell compartments, the levels of RONS attained in the cell are 
crucial for their influence on cell fate. At physiological low levels, RONS functions as ‘redox 
messengers’ in cellular signaling and regulation, whereas excess ROS induce various oxidative 
damage to proteins, lipids and DNA. In turn these alterations inactivate metabolic enzymes, 
ionic pumps, and structural proteins, disrupt cell membranes and break nucleic acids, resulting 
in the dysfunction of multiple cellular processes [84], [85], [86].  
Due to the short life time of radicals, this process seems to be time dependent, as pre - 
treatment of the medium and storage of the medium for over an hour before applying it onto 
the cells reduced the effect of CAP on cell proliferation (figure 12). Applying pre - treated 
medium immediately to LN18 cells showed only minor reduction of proliferation compared to 
treatment of cells in medium (figure 12), as also issued by Vandamme and co-workers for 
U98MG cells treated with plasma floating electrode dielectric barrier discharge (FE - DBD) [87], 
[34]. To minimize the influence of medium on the CAP effects on cells, further experiments 
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were carried out with as less liquid as possible without damaging the cells (figure 13A). This 
composition resembles the situation in the patient/ tissue, where cells are enclosed by a thin 
film of liquid.  
 
 
2. Effects of CAP on TMZ -resistant and -sensitive glioma cell lines 
Up to now the methylation status of the MGMT promoter is the only predictive marker in 
glioblastoma. Patients with an epigenetically silenced MGMT promoter (MGMT negative) have 
an improved median overall survival when treated with TMZ [88]. No alternative therapy exists 
for patients with an unfavorable MGMT promoter methylation status (MGMT positive). 
Therefore both MGMT negative and positive cell lines (figure 14A) were analyzed concerning 
their response to TMZ and CAP. TMZ offered only minor effects on the proliferation of glioma 
cell lines, especially on the cell lines with an unmethylated MGMT promoter (figure 14B). 
Noteworthy, the inhibition of cell proliferation by TMZ was less than published by others before, 
who showed a reduction of 20 - 40 percent by similar TMZ concentrations. CAP treatment, 
however, had a distinct effect on proliferation, as it reduced the viability by 50 – 80 percent 
independent of the MGMT status of the cells (figure 14C). Together with the reduced clonogenic 
potential observed in both TMZ -resistant and -sensitive cell lines (figure 19), the present data 
indicate that CAP might be a novel treatment option in TMZ -resistant cell.  
Nevertheless, it was not possible to detect induction of severe apoptosis by immunoblotting for 
the apoptosis marker Caspase 3 and Caspase 9 between 4 h and 72 h after CAP treatment 
(figure 15B and 15C). Using a plasma jet device other groups were able to show apoptosis by 
Annexin V staining and TUNEL in neuroblastoma [43], in melanoma cells [89] and pancreatic 
cells [39]. The DNA damage markers yH2AX and cleaved PARP1 were only present 48 h and 72 h, 
respectively, after CAP treatment using the SMD device (figure 15A), indicating that primary CAP 
effect on glioma cells might not be the induction of apoptosis but may ultimately lead to severe 
damage of the cells. 
 The robust induction of a cell cycle arrest in the G2/ M phase rather than induction of apoptosis 
(no sub-G1 DNA content present) after CAP application is in line with observations of TMZ 
effects in glioblastoma (figure 17). It is known that DNA lesions induced by TMZ lead to cell cycle 
arrest in S or G2/ M phase and senescence instead of direct apoptosis [90], [91], [92]. Glioma 
cells often feature DNA modifications of genes that are important for efficient DNA repair and 
cell fate. The role of p53 was described by Hirose, demonstrating that in p53 - proficient human 
glioma cells TMZ did not induced apoptosis but rather a prolonged, p53 - associated G2/ M 
arrest and senescence [93]. Only a small fraction of cells underwent apoptosis. p53 is not 
necessary for this G2/ M arrest to occur but is important for the duration of G2/ M arrest and 
the ultimate fate of TMZ - treated cells. In addition, DNA lesions induced by TMZ activate the 
p53 - controlled DNA damage response pathway. Activation of p53 suppresses MGMT gene 
Discussion 
59 
 
activity after TMZ exposure. Consequently, tumors containing wild-type p53 are more 
responsive to TMZ than tumors containing mutant p53 [94], [95]. In the present investigation, 
most cell lines used in cell cycle experiments had mutated p53 (LN18, LN229, T98G). Hirose and 
colleagues demonstrated that the p53 wild type cell line U87MG underwent G2/ M arrest 
associated with Chk1 activation and phosphorylation of both Cdc25 and Cdc2 when treated with 
TMZ [92].  
 
Our findings were supported by the publication on successful CAP treatment of glioma cells in a 
subcutaneous mouse model [96]. Here the authors could demonstrate potential antitumor 
effects of FE-DBD plasma on U87MG-Luc cells in vitro and in glioma xenografts by repeated 
treatments (five days 6 min each). They confirmed a power input dependent cell cycle arrest in S 
phase (low and high power) or G2/ M phase (only low power), leading to cell death especially 
for the high power mode. An increase in DNA damage was observed for both power settings 1 h 
after treatment (20 and 40 percent, respectively). In vivo CAP treatment of subcutaneous 
implanted U87MG cells for 5 days/ 6 minutes consecutively revealed a significant lower tumor 
volume compared to untreated tumors. Vandamme and colleagues speculate that plasma 
components act either by penetrating in the tissue or by inducing ROS releases in the tumor. 
Recent publications demonstrated beneficial effects of CAP in various in vivo models of tumors, 
among melanoma, pancreas carcinoma and neuroblastoma [35], [39], [43]. 
 
One of the most important hallmarks of malignant gliomas is their ability to infiltrate diffusely 
into the normal brain parenchyma. At the clinical level, the diffuse nature of GBMs can be 
illustrated by the fact that after surgical resection, a residual pool of invasive cells gives rise to a 
recurrent tumor. More than 90% of the cases develop immediately adjacent to the resection 
margin or within several centimeters of the resection cavity, but satellite lesions may also occur 
at a distance from the resection cavity and even in the contralateral hemisphere. Thus, 
migration and invasive behavior is a critical issue to therapy success. Cell adhesion, motility and 
invasion require receptor turnover (adhesion) and the reorganization of cytoskeleton elements 
(motility) creating an intercellular space in which invading cells can migrate (invasion) [97]. 
Using a wound healing assay we found reduced migration in glioma cells after CAP treatment in 
both TMZ -resistant and -sensitive cell lines when treated for 120 seconds and longer (figure 
20). It is well known that CAP is capable of modifying surfaces, which is i.e. utilized for surface 
sterilization. The observed disruption of migration therefore might be due to alterations on the 
dish surface leading to detachment of the cells and/ or the inability of cells to (re-) attach. 
Moreover, CAP might be able to alter cell - cell interactions and adhesive abilities of cells with 
specific extracellular matrix (ECM) components. The induction of large openings of tight 
junctions by plasma jet treated medium [98] and loss of adhesion by treatment with a plasma 
needle [99], [100] are still under discussion. 
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3. Combined treatment with CAP and chemotherapy 
The present results indicate that CAP is capable of restoring the sensitivity of TMZ -resistant 
cells towards chemotherapy. Concomitant treatment with a single application of CAP and 
repeated administration of TMZ revealed synergistic effects even in resistant cells (figure 21 and 
22). Cells treated with a combined therapy comprising 30 seconds (LN18, T98G, U87MG) or 60 
seconds (LN229) of CAP and concomitant TMZ administration (50 µM, 100 µM or 200 µM) for 
three days displayed a significant reduction of cell viability (figure 21). Combined therapy was 
not only more effective compared to exclusive treatment with TMZ or CAP, but it revealed 
synergistic effects. Notably, combined treatment with 30 seconds plus 50 µM of TMZ and 
combination of 30 seconds of CAP plus 100 µM of TMZ, respectively, revealed stronger 
inhibition compared to higher dosage of TMZ (200 µM and 100 µM, respectively) in the LN18 
and U87MG cell lines. Thus, concomitant therapy with CAP and TMZ significantly increases the 
effectiveness of TMZ both in cells with favorable and unfavorable MGMT status.  
Furthermore, cell cycle arrest after CAP treatment was found to be prominent in glioma cells 
that are unsusceptible towards treatment with TMZ for up to 200 µM in vitro (figure 22). A 
remarkable induction of a cell cycle arrest in the G2/ M phase in the TMZ -resistant cell line 
LN18 after CAP treatment of 60 seconds and longer or, 120 seconds and longer, respectively in 
the T98G cells was noticed. Only administration of high dosage of 500 µM of TMZ could induce a 
similar cell cycle arrest in these resistant cell lines. In contrast, a combined treatment of 60 
seconds of CAP and 50 µM TMZ led to a cell cycle arrest, the combination of 60 seconds of CAP 
with 100 µM or 200 µM achieved an even more distinct arrest.  
Keeping in mind that achievable TMZ levels in glioblastoma patients do not exceed 50 µM in the 
blood plasma and 5 - 10 µM in the cerebrospinal fluid [101], [102], an efficacy of a combined 
reduced dosage of TMZ with an additive therapy is desirable. In order to compare in vitro 
concentrations and efficacy of treatment with clinical practice, determination of MTIC levels 
would be more reasonable as TMZ, a pro-drug, which is rapidly hydrolyzed to its reactive 
methylating agent MTIC after oral administration. In publications addressing cell culture 
experiments various TMZ concentrations ranging from 10 µM to 1000 µM are applied. Low 
dosage of 50 µM TMZ are often efficient to inhibit MGMT negative human GBM cells [103], 
while for inhibition of MGMT positive cells typically more than 10 fold higher concentrations are 
necessary [104].  
A mechanism, comparable to the one described by Hirose for the concomitant treatment with 
TMZ and radiation, is conceivable for the observed synergistic effects of TMZ and CAP. They 
demonstrated that TMZ induces G2/ M cell cycle arrest, thereby increasing the potential for 
radiation - induced injury because radiotherapy has maximum cytotoxic effect during this phase 
of the cell cycle [93]. A study in glioblastoma cell lines by van Rijn et al. showed that the 
application of TMZ either led to an additive or supra-additive effect when combined with 
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radiotherapy, with an altered effect depending on the particular cell line [105]. CAP therefore 
might act in synergy with TMZ and possibly by multiple mechanisms, including impairment in 
DNA repair processes or via imbalance of reactive species in the cells. In fact, it was 
demonstrated by Laval and co-workers, that nitric oxide has an inhibitory dose- and time- 
dependent effect on DNA repair enzyme MGMT [106]. 
Our results on synergistic effects in combined therapy with CAP and a chemotherapeutic is in 
line with the findings by Brullé and colleagues, who observed an induction of inhibition in MIA 
PaCa2-Luc pancreatic cell proliferation in vitro and in vivo in orthotopic xenografts by 
application of a “plasma gun” DBD. This effect could be improved by association with 
gemcitabine [42], as tumors treated with combined therapy (three times plasma for 10 min plus 
6 times gemcitabine) revealed a reduced tumor mass (33 percent reduction). 
 
 
4. CAP displays cell selectivity towards tumor cells 
A critical issue concerning CAP application is the selectivity of the treatment towards tumor 
cells. First insights into a possible cell selectivity by CAP was gained by treatment of non-
tumorous primary astrocytes and an ex vivo murine brain slice model containing implanted 
glioma cells. The significant cell cycle arrest in G2/ M phase achieved in tumor cells by 60 
seconds and longer was not detectable in primary murine astrocytes by CAP treatment times of 
up to 180 seconds (figure 23). However, an increase of cells residing in the S phase of the cell 
cycle after 180 seconds of CAP was observed. These results indicate that a “therapeutic 
window” - where tumor cells are affected but non-tumorous, healthy cells persist unharmed - 
might be found. It remains speculative why primary astrocytes are less prone to CAP treatment, 
however one hypothesis is that brain cells proliferate less than tumor cells and thus have a 
reduced uptake of reactive species produced by CAP. Furthermore, non-tumorous cells have 
lower ROS levels compared to tumor cells which exhibit a high energy metabolism. ROS 
amounts in tumor cells will reach cytotoxic levels earlier than the ones in non-tumorous cells, an 
outcome that is enforced by an insufficient anti-oxidant system in tumor cells. 
In 2010, Georgescu and Lupu were among the first to address possible selectivity of CAP 
towards cancer cells using macrophages and colon cancer cells or melanoma cells, respectively 
[107]. Other publications corroborated these findings comparing effects of CAP on melanoma 
cells and keratinocytes [108], ovarian cancer cells and fibroblasts [109], human lung cancer cell 
lines and human lung normal cell lines [110] as well as glioma cells and human embryonic 
kidney (HEK) cells [111]. The disadvantages of these approaches are the lack of comparability 
between the used cell lines and used plasma devices (e.g. glioma compared with kidney cells 
and plasma jet compared with DBD) and that the cell culture experimental settings are highly 
artificial, as the origin of the cells as well the microenvironment might be crucial for the specific 
Discussion 
62 
 
response to CAP. Furthermore, equal distribution of CAP as a gas is assured in cell culture 
settings where cells are exposed as a monolayer, but CAP might induce different effects in 
connective tissue.  
Therefore, we established an ex vivo murine organotypic brain slice culture (OSC) model where 
slices of newborn mice brain were maintained. Glioma cells expressing GFP were injected and 
proliferation and spreading of the cells was monitored for 14 days via fluorescence (figure 24). 
An advantage of the OSCs are the comparability of CAP effects on healthy and tumorous cells of 
the same origin plus the possibility to investigate CAP effects on tumor cells in tissue eliminating 
the influence of liquids on the effect(s). An in vivo subcutaneous mouse model as utilized by 
Vandamme et al. [41], [96] also lacks the desirable microenvironment of the tumor and leaves 
the open - ended question how plasma could reach the tumor through the skin as the 
penetration depth for DBD and Plasma jet devices was found to be ~ 50 µm [112], [39]. An 
intracranial animal model on the other hand would require a particularly small and flexible 
plasma device featuring the same characteristics as the FlatPlaSter, which was not available by 
the time.   
Fluorescence microscopy of the OSCs containing LN18pEGFP 14 days after implantation retained 
cells migrated within the slice thickness rather than on the surface of the slice (figure 24), which 
is in line with the observation made by Boüard et al. [113] and Ohnishi et al. [114]. GFP 
expressing tumor cells were located 80 - 160 µm within the slices, illustrating migration and 
viability of the cells after 14 days. These results corroborate OSCs as a promising model for 
investigating the CAP effects on cancer cell proliferation, migration and cell selectivity. 
Noteworthy, four times of CAP application of 60 seconds and longer reduced the external 
diameter of the grown tumor consistent of LN18 glioma cells in the OSCs, but did not 
significantly reduce the migration depth within the tissue. Histological analyzes of the tissue 
after 14 days clearly demonstrated tumor formation shown by staining with HE, GFAP, Mib-1 
and mut p53 (figure 25A). Unfortunately, large necrotic areas even within the untreated slices 
hamper a distinct statement on cell selectivity. Nevertheless, preliminary data on staining with 
p-Cdc25c suggest a possible induction of cell cycle arrest in the CAP treated tumor cells 
compared to the control (figure 25B). Cell division cycle 25 (Cdc25a, b and c) phosphatases 
regulate key transitions between cell cycle phases during normal cell division, and in the event 
of DNA damage or genotoxic stress they are main targets of the checkpoint machinery that 
ensures genetic stability. The dysregulation of Cdc25 phosphatases is often involved in 
malignant transformation while overexpression is correlated with poor prognosis in many 
diverse cancers. The inhibition of these proteins therefore represents an attractive therapeutic 
target in oncology. In eukaryotic cells the three major checkpoints are the transition from G1 to 
S phase, the intra - S phase and the transition from G2 phase to mitosis. Replication errors, 
stalled replication forks or damaged DNA by extracellular factors such as UV light or ionizing 
radiation is sensed by the ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) 
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kinase families. Activation of ATM and/ or ATR is necessary to coordinate cell cycle arrest, to 
stabilize the replication fork and for mediating DNA repair. Cell cycle arrest is imposed by 
activation of two downstream kinases, Chk1 and Chk2. Chk1 is activated by DNA damage during 
interphase, whereas Chk2 is activated in response to stalled replication forks during S phase. In 
human cells, Chk1 and Chk2 phosphorylate the N-terminal region of Cdc25c on Ser216. 
Phosphorylation of Cdc25c leads to 14-3-3-mediated sequestration of the phosphatases away 
from their substrates and consequential maintenance of CDK1/ cyclin B in the phosphorylated 
and inhibited state (figure 26).  
  
 
 
Figure 26: Signaling pathways of the cell cycle control. Cells exposed to ionizing radiation (IR), ultraviolet 
light (UV), chemotherapy resulting in dsb or cells with ssb as a result from stalled replication forks 
respond by activating kinases of the ataxia-telangiectasia mutated (ATM) protein family. ATM and ATM 
related (ATR) phosphorylate and activate the checkpoint kinases Chk1 and Chk2. The checkpoint kinases 
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are transducers of the DNA damage signal and both phosphorylate a number of substrates involved in 
the DNA damage response. Chk1 phosphorylates, among others, Cdc25c at Ser 216, creating a binding 
site for 14-3-3 proteins, which then act by excluding Cdc25c from the nucleus. Cytoplasmic delocalization 
of Cdc25c prevents cyclin-dependent kinase 1 (CDK1)/ cyclin B from dephoshorylation, thereby 
suppressing the promitotic activity of this complex. The G2/ M checkpoint prevents entry into mitosis 
with unrepaired DNA lesions (modified after Ashwell and Zabludoff [115]). 
 
CAP seems to act either as an external stimulus inducing genotoxic stress and activating the cell 
cycle checkpoints via phosphorylation of Cdc25c or by generating high intracellular ROS levels 
hence taking action in signaling cascades. ROS are known to influence cell cycle progression via 
phosphorylation and ubiquitination of CDKs and cell cycle regulatory molecules [116], [117]. 
Brisson et al could establish that ROS exert their effect on Cdc25 activity via enhancing 
phosphorylation of Cdc25 or alternatively through inactivation of Cdc25 by sulfonation of 
cysteine in the active site [118]. Evidence is given that intracellular formation of ROS by CAP is a 
mediator of CAP efficiency in eukaryotic cells [87], [119]. Kalghatgi and colleagues presented 
that usage of the ROS scavenger NAC completely blocked phosphorylation of H2AX after DBD 
plasma treatment of MCF10A cells, which was supported by direct measurement of intracellular 
ROS and by the formation of malondialdehyde (MDA), a lipid peroxidation product [119]. 
However, they found that DBD plasma - induced lipid peroxidation is not responsible for the 
observed DNA damage which points towards different mechanisms of CAP produced by a DBD 
compared to a SMD device. We could not observe strong induction of phosphorylation of H2AX 
nor was the ROS scavenger NAC able to block SMD induced CAP effects (data not shown). Lipid 
peroxidation, in our experimental setting, likewise was not responsible for the reduced cell 
viability and cell cycle arrest. Stable knockdown of ALDH1A1, an enzyme able to detoxify 
reactive aldehydes as MDA or 4-hydroxynonenal (4-HNE) [120], in LN18 cells treated with CAP 
did not reveal a re - established viability (supplementary data S35A) or cell cycle progression 
(supplementary data S35B). Thus, lipid peroxidation might not be the main target in glioma cells 
by CAP. Kalghatgi further proposed an ATR dependent phosphorylation of H2AX following 
plasma treatment, suggesting that CAP may lead to replication arrest or formation of single - 
stranded DNA breaks [119]. This is in line with the phosphorylation of Cdc25c in OSCs which we 
found after repeated CAP treatment. Cdc25c is a key mediator of G2/ M phase arrest 
downstream of the ATM/ ATR signaling pathway, which seems to be involved in mediating CAP 
effects in tumor cells. Further experiments need to be done to elucidate whether CAP itself 
activates this pathway by directly producing genotoxic stress or if DNA damage is induced by 
creating high intracellular ROS levels. Adjustments on OSCs and investigation of the signaling 
pathways involved in mediation of the CAP effects on eukaryotic cells are necessary and of high 
scientific interest.  
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G. Assessment and Outlook 
Application of CAP in the medical field gained a lot of interest, ranging from inactivation of 
various bacterial strains relevant in hospital hygiene, inactivation of spores and viruses to 
clinical phase II studies on the treatment of chronic wounds. In addition, CAP is a new auspicious 
candidate in cancer treatment. CAP application in the context of a broad spectrum of different 
tumor entities has been explored. Besides applied research investigating the application of CAP 
in cancer therapy, CAP treatment provides the opportunity of a deeper understanding of the 
tumor behavior regarding the role of radicals and tumor metabolism. Modification of the 
plasma chemistry produced by the device discriminating between oxygen and nitrogen based 
chemistry and investigation of the specific effects induced thereby, might provide new insights 
into tumor behavior and tumor progression. In non-tumorous tissue and cells, oxidative 
phosphorylation (OxPhos) couples ATP production to the flow of electrons through the electron 
transport chain (ETC) within the mitochondrial energy metabolism. In contrast, most cancer 
cells instead rely on aerobic glycolysis, a phenomenon known as the ‘Warburg effect’ [121], 
[122]. Based on their results with TMZ -resistant and TMZ -sensitive glioma cells, Oliva and 
colleagues proposed a new mechanism of adaptive chemoresistance in glioma cells linking both 
oxidative stress and drug resistance in cancer cells leading to a suppressed apoptotic signaling 
[123]. Low electron flux through the ETC can promote increased generation of superoxide 
radicals in cancer cells, while TMZ -resistant glioma cells under conditions of oxidative stress 
generate less ROS probably due to an increased capacity for electron flux through the ETC. 
Experiments with ρ° cells lacking a functional ETC and which are incapable of generating ATP 
and ROS at the mitochondrial level, indicate that TMZ sensitivity arises from enhanced ROS 
production of the mitochondrial ETC. TMZ –resistant cells were found to have a significant 
reduced ROS production which was associated with enhanced chemoresistance. CAP efficacy in 
TMZ –resistant glioma cells might therefore result from mitochondrial – independent ROS 
production or uptake of extracellular ROS produced by CAP.    
Three main issues in cancer application of CAP are still under discussion: The topic which is 
investigated best refers to the interaction of tumors/ tumor cells with CAP. In summary, most 
investigators found a cell cycle arrest and senescence induced by low concentrations of reactive 
species (driven by low power input), whereas high density flux (high power input) led to 
apoptosis or yet necrosis. The plasma device used in the present study is working in the reactive 
oxygen species rich mode, inducing an inhibition of proliferation and a prolonged cell cycle 
arrest in the G2/ M phase. The FlatPlaSter 2.0 was operated with low power input (10 mW/ 
cm2). In contrast to devices mentioned above, the power input of the SMD device does not 
influence the density of total reactive species. The key characteristic using the low power input 
is the production of mainly reactive oxygen species, like ozone. As stated in the introduction, 
high power input generates nitrogen based chemistry and less oxygen based species. 
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Differences in cell fate seem to be dependent on the type of tumor cell as well as the plasma 
device and the produced plasma chemistry. Outstanding is the observed efficacy of CAP 
treatment in TMZ -sensitive and -resistant glioma cells in vitro, which withstand most 
therapeutic modalities so far. Combined therapy of CAP and TMZ discovered synergistic effects 
in resistant glioma cells, restoring sensitivity of chemoresistant cells towards therapy with the 
alkylating agent TMZ.  
The second main topic concerning CAP in cancer treatment is the mechanism that promotes 
CAP effects on tumor cells. A raising number of publications propose the produced reactive 
oxygen and nitrogen species (ROS and RNS) to induce anti-cancer effects separately or in 
conjunction with the UV light or the electrical field produced. Interactions on the cell surface are 
believed to play an important role, as formation of “nanoholes” or pore opening by lipid 
peroxidation of the membrane could mediate CAP effects [124], [125]. Yet, the composition of 
produce species by CAP is not defined completely. The characterization of the FlatPlaSter 2.0 in 
the low input power mode revealed mainly the production of oxygen - based species. The work 
presented here did not focus on these aspects of CAP application, as the characterization of the 
device was conducted simultaneously with the experiments on cells. Moreover, it remains 
unsettled which reactive species and components effectively reach the desired cells/ tissue. The 
distance between electrode and cells/ tissue as well as the quantity and nature of interphase(s) 
are crucial. The distance between the electrode and the sample was set as 14 mm, thus 
electrons, ions and neutral species (long and short life time) could reach the sample. Treatment 
was carried out with only a thin film of medium covering the cells to reduce medium induced 
effects on the cells. Transport of reactive species out of discharge region, through the gas phase 
into the liquid phase clearly alters the composition of the RONS. Moreover, the presence of 
liquid can modify both the reactive oxygen and nitrogen species generated in the gas phase due 
to evaporation of water molecules. Estimation of how the produced species dissolve and react 
in liquid is important, as the amount of species dissolves in liquid depends on the kind of species 
produced. While using a SMD device, no electrical current flows through the sample in contrast 
to DBD devices which use the sample as the second electrode. Obviously, substantial 
modifications and standardized settings will be necessary to compare relevant publications.  
The third issue discussed is the cell selective property of CAP. Whereas most of the literature 
compares CAP effects on tumor cells with immortalized cell lines, additionally often derived 
from a different origin, we related the effects of CAP on glioma cells to the effects on freshly 
prepared primary astrocytes. Primary astrocytes showed a delay of induction of cell cycle arrest 
in the S phase after 180 seconds of CAP treatment. In comparison CAP treated tumor cells 
exhibited a strong cell cycle arrest in the G2/ M phase already after 60 seconds. These results 
indicated a possible ‘therapeutic window’ for the treatment of glioma cells by this SMD device. 
Advancement was made by establishing an orthotopic ex vivo model of murine brain slice 
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cultures. This model enables addressing both efficacy of tumor inhibition and cell selectivity of 
CAP in the appropriate microenvironment of the tumor.  
A possible proposal regarding clinical applications of this technology would be an “endoscopic” 
device, which is flexible and would be applicable in difficult to access regions. Following primary 
resection CAP application of the surgical cavity would be beneficial in eliminating microscopic 
residues of the tumor, thereby limiting recurrent disease. CAP would synergize best with an 
intra - operative chemotherapy such as Gliadel, as the CAP effect on cell cycle inhibition persists 
on the order of days (figure 18) [126]. We are hopeful that delivery of CAP will be feasible 
during surgery, permitting treatment of tumor beds and novel localization beyond superficial 
treatment. Obviously, significant modifications and improvements to the technology will be 
necessary to realize this ambition.  
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H. Supplementary Data 
 
Supplementary figure S26: PH change of DMEM supplemented with 1% FCS after CAP  
 
 
 
Supplementary figure S27: CAP effects on FCS 
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Supplementary figure S28: Western blot detection of DNA damage and induction of apoptosis in LN229 
cells treated with CAP 
 
 
  
Figure S28: Immunoblotting revealed cleavage of PARP1 and activation of H2AX after 48 and 72 h in 
LN229 glioma cells. 
 
 
Supplementary figure S29: Comet assay of LN229 glioma cells after CAP 
A 
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Figure S29: Comet assay analyzing OTM (A), percentage of DNA in tail (B) and testing for viability of the 
cells.  Cell pellets from LN229 cells were resuspended 0.7 % low-melting agarose and applied to slides 
frosted at the edges and covered with 0.5 % normal melting agarose. For cell lysis slides were placed in 
alkali solution for 1 h. Prior to electrophoresis, the slides were placed in a horizontal gel electrophoresis 
chamber and incubated with alkaline buffer solution at pH 13.2. After 20 min of DNA unwinding, 
electrophoresis was started. Following neutralization fluorescent DNA staining was performed with 
ethidium bromide. Slides were analyzed and 80 cell nuclei per slide (2 slides per each CAP treatment) 
were selected with random pattern and digitized with the monochrome CCD camera (Cohu Inc., San 
Diego, CA, USA). Migration was measured by the image analysis software Komet++ (Kinetic Imaging, 
Liverpool, UK) using the % of DNA in tail and the Olive Tail Moments (OTM). The OTM represents the 
multiplication of the relative amount of DNA in the tail with the median migration distance. The % tail 
DNA is a measure of the relative fluorescent intensity in the head and tail. An OTM above 2 is widely 
accepted as DNA damage. 
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Supplementary figure S30: Cell cycle arrest is induced after CAP  
A 
 
 
B 
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Figure S30: Cell cycle distribution of glioma cells after CAP application. A LN18 cells (TMZ-resistant) 
were CAP treated and flow cytometry was performed 24 h, 48 h and 72 h afterwards. B Cell cycle 
analysis of LN229 (TMZ-sensitive) after CAP application. C T98G (TMZ-resistant) cells were CAP treated 
and cell cycle distribution was detected 48 h afterwards. D Mean proportion of cells in G2/ M phase after 
CAP application in three independent experiments (P-value*** < 0.001) of LN229 cells and E of T98G 
cells.  
Supplementary figure S31: Concomitant therapy with CAP and TMZ features synergistic effects in 
glioma cells 
A 
 
B 
 
 
Figure S31: A T98G cells were first CAP treated once and TMZ was applied three days consecutively later. 
Viability was measured using MTT assay. B Viability of the LN229 cells after a single CAP treatment 
followed by three days of consecutive TMZ application.  
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Supplementary figure S32: Resistant glioma cells were re-sensitized of towards therapy with TMZ by 
CAP 
 
 
Figure S32: Combined treatment of CAP and TMZ was able to induce cell cycle arrest in resistant T98G 
cells. Cell cycle distribution of T98G cells after either TMZ alone (up to 500 µM) or concomitant 
treatment with CAP and TMZ (60 seconds plus TMZ).  
Supplementary figure S33: CAP revealed similar effects on proliferation of LN18pEGFP compared to 
LN18 wt cells 
 
 
Figure S33: LN18pEGFP cells respond to treatment with CAP and TMZ similar to LN18 wt cells. 
LN18pEGFP cells were either CAP or TMZ (three days consecutively) treated and cell proliferation was 
measured afterwards. 
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Supplementary figure S34: Orthotopic brain slides cultures as a model for CAP selectivity 
 
Figure S34: CAP displays cell selective properties. LN18pEGFP cells were transplanted onto orthotopic 
murine brain slices and allow settling for 24 h before CAP was applied onto the slices. Slices containing 
fluorescence expressing LN18 cells were monitored before and 14 days after CAP application.  
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Supplementary figure S35: ALDH1A1 knock down in glioma cells does not influence the effects of CAP 
on these cells 
 
A 
 
 
B 
 
 
 
Figure S35: Lipid peroxidation induced by CAP might not be responsible for DNA damage in ALDH1A1 
depleted glioma cells.  ALDH1A1 was knocked down in LN18 cells and shRNA, mock and control cells 
were CAP treated. A Proliferation after CAP treatment for 30 seconds and 120 seconds was detected in 
LN18shRNA, LN18 mock and LN18 wt cells. B Cell cycle distribution 48 h after CAP treatment was 
analyzed in LN18 wt, LN18 ALDH1shRNA depleted and LN18 mock cells. 
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J. Abbreviations 
 
ALDH1A1 Aldehyde dehydrogenase 1 A1 
ATM ataxia telangiectasia mutated 
ATR ATM and Rad3-related 
BSA Bovine serum albumin 
bTSC brain Tumor Stem Cells 
CAP Cold Atmospheric Plasma 
CDK Cyclin-dependent kinase 
ChK1/ ChK2 cell cycle checkpoint kinase 1/ 2 
DBD Dielectric Barrier Discharge 
DMSO Dimethyl sulfoxide 
DSB double strand break 
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor 
ETC Electron transport chain 
FBS Fetal Bovine Serum 
FE-DBD Floating Electrode DBD 
GBM Glioblastoma 
GFAP Glial fibrillary acidic protein 
GFP Green fluorescence protein 
HE Hämatoxylin-Eosin 
HNE 4-Hydroxynonenal 
HRP Horse radish peroxidase 
IDH1/2 Isocitrate dehydrogenase 1 and 2 
LOH Loss of heterozygosity 
luc Luciferase 
MDA malondialdehyde 
MGMT O-6-methylguanine-DNA methyltransferase 
MMR Mismatch repair 
MTIC MTIC (3-methyl-(triazen-1-yl) imidazole-4-carboxamide). 
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MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
NAC N-Acetyl-L-cysteine 
O6-MG O6-methylguanine 
OSC Organotypic slice culture 
PARP1 Poly(ADP-ribose) polymerase 1 
PBS Phosphate buffered saline 
PI Propidiumiodid 
PTEN Phosphatase and tensin homolog 
RNS Reactive nitrogen species 
RONS Reactive oxygen and nitrogen species 
ROS Reactive oxygen species 
SDS-PAGE Sodium dodecyl sulfatepolyacrylamidegel electrophoresis 
Ser Serine 
shRNA short hairpin RNA 
SMD Surface Micro Discharge 
SSB single strand break 
TMZ Temozolomide 
TP53 Tumor protein p53 
TUNEL Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling 
Wt Wild-type 
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